<SEC-DOCUMENT>0001516551-22-000013.txt : 20220523
<SEC-HEADER>0001516551-22-000013.hdr.sgml : 20220523
<ACCEPTANCE-DATETIME>20220523170506
ACCESSION NUMBER:		0001516551-22-000013
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		14
CONFORMED PERIOD OF REPORT:	20220518
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20220523
DATE AS OF CHANGE:		20220523

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Skye Bioscience, Inc.
		CENTRAL INDEX KEY:			0001516551
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				450692882
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-55136
		FILM NUMBER:		22952675

	BUSINESS ADDRESS:	
		STREET 1:		11250 EL CAMINO REAL, SUITE 100
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92130
		BUSINESS PHONE:		(858) 410-0266

	MAIL ADDRESS:	
		STREET 1:		11250 EL CAMINO REAL, SUITE 100
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92130

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Emerald Bioscience, Inc.
		DATE OF NAME CHANGE:	20190325

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Nemus Bioscience, Inc.
		DATE OF NAME CHANGE:	20141030

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	LOAD GUARD LOGISTICS, INC.
		DATE OF NAME CHANGE:	20121107
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>skye-20220518.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2022 Workiva--><!--r:dc1fbabb-1639-4b5a-baab-8e85f16f98d4,g:97730539-3d09-442b-b5a0-dc05c4ac6ccc,d:1189c7fb5d1444d1abc194af3b75a3e5--><html xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:dei="http://xbrl.sec.gov/dei/2021" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns="http://www.w3.org/1999/xhtml" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>skye-20220518</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="i3e6150910ed944fd9b7905d8ded31c91_D20220518-20220518" name="dei:AmendmentFlag" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjExODljN2ZiNWQxNDQ0ZDFhYmMxOTRhZjNiNzVhM2U1L3NlYzoxMTg5YzdmYjVkMTQ0NGQxYWJjMTk0YWYzYjc1YTNlNV80L2ZyYWc6OGU3MTdiOWZkMjZjNDlhMmE5Zjc2NjY5NTM5OWIxZTYvdGFibGU6MWEwMTc4ZTEyYzFjNDQzYjgwYzM3ZGU0MjY4NGE1ZWEvdGFibGVyYW5nZToxYTAxNzhlMTJjMWM0NDNiODBjMzdkZTQyNjg0YTVlYV8wLTEtMS0xLTU3ODk0_ef1a55f0-cab6-4469-ba02-958dcd7cb5bc">FALSE</ix:nonNumeric><ix:nonNumeric contextRef="i3e6150910ed944fd9b7905d8ded31c91_D20220518-20220518" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOjExODljN2ZiNWQxNDQ0ZDFhYmMxOTRhZjNiNzVhM2U1L3NlYzoxMTg5YzdmYjVkMTQ0NGQxYWJjMTk0YWYzYjc1YTNlNV80L2ZyYWc6OGU3MTdiOWZkMjZjNDlhMmE5Zjc2NjY5NTM5OWIxZTYvdGFibGU6MWEwMTc4ZTEyYzFjNDQzYjgwYzM3ZGU0MjY4NGE1ZWEvdGFibGVyYW5nZToxYTAxNzhlMTJjMWM0NDNiODBjMzdkZTQyNjg0YTVlYV8xLTEtMS0xLTU3ODk0_c28e627e-6237-4c88-ade4-dc48ac4f42e2">0001516551</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="skye-20220518.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="i3e6150910ed944fd9b7905d8ded31c91_D20220518-20220518"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-18</xbrli:startDate><xbrli:endDate>2022-05-18</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i1189c7fb5d1444d1abc194af3b75a3e5_1"></div><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">WASHINGTON, D.C. 20549</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FORM&#160;<ix:nonNumeric contextRef="i3e6150910ed944fd9b7905d8ded31c91_D20220518-20220518" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjExODljN2ZiNWQxNDQ0ZDFhYmMxOTRhZjNiNzVhM2U1L3NlYzoxMTg5YzdmYjVkMTQ0NGQxYWJjMTk0YWYzYjc1YTNlNV8xL2ZyYWc6MzRhMTFjMzU4NmFiNGIxM2I0YTIyYzgzNmQ5NWYwYTYvdGV4dHJlZ2lvbjozNGExMWMzNTg2YWI0YjEzYjRhMjJjODM2ZDk1ZjBhNl8xMTE1_45332661-531f-4978-bcfb-803f76e8dd63">8-K</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CURRENT REPORT</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Pursuant to Section&#160;13 or 15(d)&#160;of</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">the Securities Exchange Act of 1934</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Date of report (Date of earliest event reported): <ix:nonNumeric contextRef="i3e6150910ed944fd9b7905d8ded31c91_D20220518-20220518" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOjExODljN2ZiNWQxNDQ0ZDFhYmMxOTRhZjNiNzVhM2U1L3NlYzoxMTg5YzdmYjVkMTQ0NGQxYWJjMTk0YWYzYjc1YTNlNV8xL2ZyYWc6MzRhMTFjMzU4NmFiNGIxM2I0YTIyYzgzNmQ5NWYwYTYvdGV4dHJlZ2lvbjozNGExMWMzNTg2YWI0YjEzYjRhMjJjODM2ZDk1ZjBhNl8yMzA_37b95c44-489e-4b30-a6d9-2cd4f2a930fc">May 18, 2022</ix:nonNumeric></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:28.993%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i3e6150910ed944fd9b7905d8ded31c91_D20220518-20220518" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjExODljN2ZiNWQxNDQ0ZDFhYmMxOTRhZjNiNzVhM2U1L3NlYzoxMTg5YzdmYjVkMTQ0NGQxYWJjMTk0YWYzYjc1YTNlNV8xL2ZyYWc6MzRhMTFjMzU4NmFiNGIxM2I0YTIyYzgzNmQ5NWYwYTYvdGV4dHJlZ2lvbjozNGExMWMzNTg2YWI0YjEzYjRhMjJjODM2ZDk1ZjBhNl8xMTE2_40a8f163-be9f-4f5f-bc9d-2d6a098ad92d">SKYE BIOSCIENCE, INC.</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:28.993%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:31.018%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.883%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.018%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.883%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.498%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i3e6150910ed944fd9b7905d8ded31c91_D20220518-20220518" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOjExODljN2ZiNWQxNDQ0ZDFhYmMxOTRhZjNiNzVhM2U1L3NlYzoxMTg5YzdmYjVkMTQ0NGQxYWJjMTk0YWYzYjc1YTNlNV8xL2ZyYWc6MzRhMTFjMzU4NmFiNGIxM2I0YTIyYzgzNmQ5NWYwYTYvdGFibGU6NzgzNzI2ZGFjY2JkNDZlMjgxZWQwNzkwOGZjYzkxMmIvdGFibGVyYW5nZTo3ODM3MjZkYWNjYmQ0NmUyODFlZDA3OTA4ZmNjOTEyYl8wLTAtMS0xLTU3ODk0_31179a7d-d3cc-4244-a963-5856a3b46155">Nevada</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i3e6150910ed944fd9b7905d8ded31c91_D20220518-20220518" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOjExODljN2ZiNWQxNDQ0ZDFhYmMxOTRhZjNiNzVhM2U1L3NlYzoxMTg5YzdmYjVkMTQ0NGQxYWJjMTk0YWYzYjc1YTNlNV8xL2ZyYWc6MzRhMTFjMzU4NmFiNGIxM2I0YTIyYzgzNmQ5NWYwYTYvdGFibGU6NzgzNzI2ZGFjY2JkNDZlMjgxZWQwNzkwOGZjYzkxMmIvdGFibGVyYW5nZTo3ODM3MjZkYWNjYmQ0NmUyODFlZDA3OTA4ZmNjOTEyYl8wLTItMS0xLTU3ODk0_f772e67c-982b-4e29-89bd-e76dc86d6746">000-55136</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i3e6150910ed944fd9b7905d8ded31c91_D20220518-20220518" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOjExODljN2ZiNWQxNDQ0ZDFhYmMxOTRhZjNiNzVhM2U1L3NlYzoxMTg5YzdmYjVkMTQ0NGQxYWJjMTk0YWYzYjc1YTNlNV8xL2ZyYWc6MzRhMTFjMzU4NmFiNGIxM2I0YTIyYzgzNmQ5NWYwYTYvdGFibGU6NzgzNzI2ZGFjY2JkNDZlMjgxZWQwNzkwOGZjYzkxMmIvdGFibGVyYW5nZTo3ODM3MjZkYWNjYmQ0NmUyODFlZDA3OTA4ZmNjOTEyYl8wLTQtMS0xLTU3ODk0_7e35f3d8-0401-4e30-84a6-7e3ff5de334c">45-0692882</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(State or other jurisdiction of incorporation)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Commission File Number)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(I.R.S. Employer Identification Number)</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><ix:nonNumeric contextRef="i3e6150910ed944fd9b7905d8ded31c91_D20220518-20220518" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOjExODljN2ZiNWQxNDQ0ZDFhYmMxOTRhZjNiNzVhM2U1L3NlYzoxMTg5YzdmYjVkMTQ0NGQxYWJjMTk0YWYzYjc1YTNlNV8xL2ZyYWc6MzRhMTFjMzU4NmFiNGIxM2I0YTIyYzgzNmQ5NWYwYTYvdGFibGU6OWIxZTJjZTYzN2FkNDdhM2FhOTM1MGJmZTdkMDc3MjEvdGFibGVyYW5nZTo5YjFlMmNlNjM3YWQ0N2EzYWE5MzUwYmZlN2QwNzcyMV8wLTAtMS0xLTU3ODk0L3RleHRyZWdpb246NjJiODY3Y2RkNTIxNDc5OGI0YjhmMGNjY2VkYTFjOGJfNA_b3dfcc94-c972-4a99-b9ca-0c585b870642">11250 El Camino Real</ix:nonNumeric>,  <ix:nonNumeric contextRef="i3e6150910ed944fd9b7905d8ded31c91_D20220518-20220518" name="dei:EntityAddressAddressLine2" id="id3VybDovL2RvY3MudjEvZG9jOjExODljN2ZiNWQxNDQ0ZDFhYmMxOTRhZjNiNzVhM2U1L3NlYzoxMTg5YzdmYjVkMTQ0NGQxYWJjMTk0YWYzYjc1YTNlNV8xL2ZyYWc6MzRhMTFjMzU4NmFiNGIxM2I0YTIyYzgzNmQ5NWYwYTYvdGFibGU6OWIxZTJjZTYzN2FkNDdhM2FhOTM1MGJmZTdkMDc3MjEvdGFibGVyYW5nZTo5YjFlMmNlNjM3YWQ0N2EzYWE5MzUwYmZlN2QwNzcyMV8wLTAtMS0xLTU3ODk0L3RleHRyZWdpb246NjJiODY3Y2RkNTIxNDc5OGI0YjhmMGNjY2VkYTFjOGJfOQ_6c58834e-12ea-4ee5-86e5-8867b7c68ef5">Suite 100</ix:nonNumeric>, <ix:nonNumeric contextRef="i3e6150910ed944fd9b7905d8ded31c91_D20220518-20220518" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOjExODljN2ZiNWQxNDQ0ZDFhYmMxOTRhZjNiNzVhM2U1L3NlYzoxMTg5YzdmYjVkMTQ0NGQxYWJjMTk0YWYzYjc1YTNlNV8xL2ZyYWc6MzRhMTFjMzU4NmFiNGIxM2I0YTIyYzgzNmQ5NWYwYTYvdGFibGU6OWIxZTJjZTYzN2FkNDdhM2FhOTM1MGJmZTdkMDc3MjEvdGFibGVyYW5nZTo5YjFlMmNlNjM3YWQ0N2EzYWE5MzUwYmZlN2QwNzcyMV8wLTAtMS0xLTU3ODk0L3RleHRyZWdpb246NjJiODY3Y2RkNTIxNDc5OGI0YjhmMGNjY2VkYTFjOGJfMTM_132da7b1-5105-4dde-9a8a-00dd12bbbaf0">San Diego</ix:nonNumeric>, <ix:nonNumeric contextRef="i3e6150910ed944fd9b7905d8ded31c91_D20220518-20220518" name="dei:EntityAddressStateOrProvince" id="id3VybDovL2RvY3MudjEvZG9jOjExODljN2ZiNWQxNDQ0ZDFhYmMxOTRhZjNiNzVhM2U1L3NlYzoxMTg5YzdmYjVkMTQ0NGQxYWJjMTk0YWYzYjc1YTNlNV8xL2ZyYWc6MzRhMTFjMzU4NmFiNGIxM2I0YTIyYzgzNmQ5NWYwYTYvdGFibGU6OWIxZTJjZTYzN2FkNDdhM2FhOTM1MGJmZTdkMDc3MjEvdGFibGVyYW5nZTo5YjFlMmNlNjM3YWQ0N2EzYWE5MzUwYmZlN2QwNzcyMV8wLTAtMS0xLTU3ODk0L3RleHRyZWdpb246NjJiODY3Y2RkNTIxNDc5OGI0YjhmMGNjY2VkYTFjOGJfMTc_4d18a667-5fa0-4a05-9b6b-0cb8ded17566">CA</ix:nonNumeric> <ix:nonNumeric contextRef="i3e6150910ed944fd9b7905d8ded31c91_D20220518-20220518" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOjExODljN2ZiNWQxNDQ0ZDFhYmMxOTRhZjNiNzVhM2U1L3NlYzoxMTg5YzdmYjVkMTQ0NGQxYWJjMTk0YWYzYjc1YTNlNV8xL2ZyYWc6MzRhMTFjMzU4NmFiNGIxM2I0YTIyYzgzNmQ5NWYwYTYvdGFibGU6OWIxZTJjZTYzN2FkNDdhM2FhOTM1MGJmZTdkMDc3MjEvdGFibGVyYW5nZTo5YjFlMmNlNjM3YWQ0N2EzYWE5MzUwYmZlN2QwNzcyMV8wLTAtMS0xLTU3ODk0L3RleHRyZWdpb246NjJiODY3Y2RkNTIxNDc5OGI0YjhmMGNjY2VkYTFjOGJfMjA_6abebc96-efef-4492-a056-b68eb3bc92bc">92130</ix:nonNumeric></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(Address of principal executive offices)</span></div></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">(<ix:nonNumeric contextRef="i3e6150910ed944fd9b7905d8ded31c91_D20220518-20220518" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOjExODljN2ZiNWQxNDQ0ZDFhYmMxOTRhZjNiNzVhM2U1L3NlYzoxMTg5YzdmYjVkMTQ0NGQxYWJjMTk0YWYzYjc1YTNlNV8xL2ZyYWc6MzRhMTFjMzU4NmFiNGIxM2I0YTIyYzgzNmQ5NWYwYTYvdGFibGU6ZTNmZDA3N2EyZTU2NGJjYWExN2JjMmNlZWFkZTU2ZTYvdGFibGVyYW5nZTplM2ZkMDc3YTJlNTY0YmNhYTE3YmMyY2VlYWRlNTZlNl8wLTAtMS0xLTU3ODk0L3RleHRyZWdpb246MWFjNWUxYTY2M2RmNDliYjgwYzZhNDE5NDk1ZDkxNjhfNQ_8b5d58e0-33fd-4c0c-8e6b-eccdb510e50d">858</ix:nonNumeric>) <ix:nonNumeric contextRef="i3e6150910ed944fd9b7905d8ded31c91_D20220518-20220518" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOjExODljN2ZiNWQxNDQ0ZDFhYmMxOTRhZjNiNzVhM2U1L3NlYzoxMTg5YzdmYjVkMTQ0NGQxYWJjMTk0YWYzYjc1YTNlNV8xL2ZyYWc6MzRhMTFjMzU4NmFiNGIxM2I0YTIyYzgzNmQ5NWYwYTYvdGFibGU6ZTNmZDA3N2EyZTU2NGJjYWExN2JjMmNlZWFkZTU2ZTYvdGFibGVyYW5nZTplM2ZkMDc3YTJlNTY0YmNhYTE3YmMyY2VlYWRlNTZlNl8wLTAtMS0xLTU3ODk0L3RleHRyZWdpb246MWFjNWUxYTY2M2RmNDliYjgwYzZhNDE5NDk1ZDkxNjhfOQ_677d86e4-d259-490f-a39d-45abe8ec396f">410-0266</ix:nonNumeric></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Registrant&#8217;s telephone number, including area code)</span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">_________________________</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Former name or former address, if changed since last report)</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Check the appropriate box below if the Form&#160;8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions.</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:5.844%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:91.956%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i3e6150910ed944fd9b7905d8ded31c91_D20220518-20220518" name="dei:WrittenCommunications" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjExODljN2ZiNWQxNDQ0ZDFhYmMxOTRhZjNiNzVhM2U1L3NlYzoxMTg5YzdmYjVkMTQ0NGQxYWJjMTk0YWYzYjc1YTNlNV8xL2ZyYWc6MzRhMTFjMzU4NmFiNGIxM2I0YTIyYzgzNmQ5NWYwYTYvdGFibGU6Njk5MmNlY2JjYjdiNGZmZGE1ZGFhYzA4MmZjMDU0ZDcvdGFibGVyYW5nZTo2OTkyY2VjYmNiN2I0ZmZkYTVkYWFjMDgyZmMwNTRkN18wLTAtMS0xLTU3ODk0_401ce26e-387d-4d3a-ab36-3586e687531f">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Written communications pursuant to Rule&#160;425 under the Securities Act (17 CFR 230.425)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i3e6150910ed944fd9b7905d8ded31c91_D20220518-20220518" name="dei:SolicitingMaterial" format="ixt:fixed-true" id="id3VybDovL2RvY3MudjEvZG9jOjExODljN2ZiNWQxNDQ0ZDFhYmMxOTRhZjNiNzVhM2U1L3NlYzoxMTg5YzdmYjVkMTQ0NGQxYWJjMTk0YWYzYjc1YTNlNV8xL2ZyYWc6MzRhMTFjMzU4NmFiNGIxM2I0YTIyYzgzNmQ5NWYwYTYvdGFibGU6Njk5MmNlY2JjYjdiNGZmZGE1ZGFhYzA4MmZjMDU0ZDcvdGFibGVyYW5nZTo2OTkyY2VjYmNiN2I0ZmZkYTVkYWFjMDgyZmMwNTRkN18xLTAtMS0xLTU3ODk0_850a437d-fbbc-489d-a406-da266f4956a9">x</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Soliciting material pursuant to Rule&#160;14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i3e6150910ed944fd9b7905d8ded31c91_D20220518-20220518" name="dei:PreCommencementTenderOffer" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjExODljN2ZiNWQxNDQ0ZDFhYmMxOTRhZjNiNzVhM2U1L3NlYzoxMTg5YzdmYjVkMTQ0NGQxYWJjMTk0YWYzYjc1YTNlNV8xL2ZyYWc6MzRhMTFjMzU4NmFiNGIxM2I0YTIyYzgzNmQ5NWYwYTYvdGFibGU6Njk5MmNlY2JjYjdiNGZmZGE1ZGFhYzA4MmZjMDU0ZDcvdGFibGVyYW5nZTo2OTkyY2VjYmNiN2I0ZmZkYTVkYWFjMDgyZmMwNTRkN18yLTAtMS0xLTU3ODk0_d561d588-d0f6-4593-816c-a0400a7c9676">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pre-commencement communications pursuant to Rule&#160;14d-2(b)&#160;under the Exchange Act (17 CFR 240.14d-2(b))</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i3e6150910ed944fd9b7905d8ded31c91_D20220518-20220518" name="dei:PreCommencementIssuerTenderOffer" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjExODljN2ZiNWQxNDQ0ZDFhYmMxOTRhZjNiNzVhM2U1L3NlYzoxMTg5YzdmYjVkMTQ0NGQxYWJjMTk0YWYzYjc1YTNlNV8xL2ZyYWc6MzRhMTFjMzU4NmFiNGIxM2I0YTIyYzgzNmQ5NWYwYTYvdGFibGU6Njk5MmNlY2JjYjdiNGZmZGE1ZGFhYzA4MmZjMDU0ZDcvdGFibGVyYW5nZTo2OTkyY2VjYmNiN2I0ZmZkYTVkYWFjMDgyZmMwNTRkN18zLTAtMS0xLTU3ODk0_1b893c46-3e0a-4d03-bc4c-9e511454f849">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pre-commencement communications pursuant to Rule&#160;13e-4(c)&#160;under the Exchange Act (17 CFR 240.13e-4(c))</span></td></tr></table></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</span></div><div style="padding-left:288pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Emerging growth company  </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i3e6150910ed944fd9b7905d8ded31c91_D20220518-20220518" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjExODljN2ZiNWQxNDQ0ZDFhYmMxOTRhZjNiNzVhM2U1L3NlYzoxMTg5YzdmYjVkMTQ0NGQxYWJjMTk0YWYzYjc1YTNlNV8xL2ZyYWc6MzRhMTFjMzU4NmFiNGIxM2I0YTIyYzgzNmQ5NWYwYTYvdGV4dHJlZ2lvbjozNGExMWMzNTg2YWI0YjEzYjRhMjJjODM2ZDk1ZjBhNl8xMTE0_e7f0d6b2-4ac2-46e7-917b-fce0b8ee78c7">&#9744;</ix:nonNumeric></span></div><div style="padding-left:288pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Securities registered pursuant to Section 12(b) of the Act:</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:80.729%"><tr><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Title of each class</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Trading</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Symbol(s)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Name of each exchange</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">on which registered</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">N/A</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">N/A</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">N/A</span></div></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#9744;</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i1189c7fb5d1444d1abc194af3b75a3e5_7"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div><span><br/></span></div><div style="-sec-extract:summary"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Item 1.01 Entry into a Material Definitive Agreement.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Support Agreements</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">As previously reported, on May 11, 2022, Skye Bioscience, Inc., a Nevada corporation (&#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">Skye</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8221;), and Emerald Health Therapeutics, Inc. a corporation existing under the laws of the Province of British Columbia, Canada (&#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">EHT</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8221;), entered into an Arrangement Agreement (the &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">Arrangement Agreement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8221;), pursuant to which Skye will acquire all of the issued and outstanding common shares of EHT (the &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">EHT Shares</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8221;) pursuant to a plan of arrangement (the &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">Plan of Arrangement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8221;) under the Business Corporations Act (British Columbia) (the &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">Arrangemen</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">t&#8221;).</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On May 18, 2022, Skye and Emerald Health Sciences, Inc. (&#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">EHS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8221;) entered into a support agreement (the &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">EHT Support Agreement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8221;), pursuant to which EHS agreed, among other things, to vote their EHT Shares in favor of the approval of the Arrangement and against any alternative proposal. The EHT Support Agreement terminates upon the occurrence of certain events, including the termination of the Arrangement Agreement in accordance with its terms.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The foregoing description of the EHT Support Agreement does not purport to be complete and is qualified in its entirety by reference to the EHT Support Agreement, which is attached as Exhibit 10.1 to this Current Report on Form 8-K and is incorporated herein by reference.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On May 18, 2022, EHT and EHS entered into a support agreement (the &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">Skye Support Agreement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8221;), pursuant to which EHS agreed, among other things, to vote their shares of Skye Common Stock in favor of the adoption of the Arrangement Agreement and against any alternative proposal. The Skye Support Agreement terminates upon the occurrence of certain events, including the termination of the Arrangement Agreement in accordance with its terms.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The foregoing description of the Skye Support Agreement does not purport to be complete and is qualified in its entirety by reference to the Skye Support Agreement, which is attached as Exhibit 10.2 to this Current Report on Form 8-K and is incorporated herein by reference.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On May 18, 2022, Jim Heppell resigned as a member of Skye&#8217;s board of directors, audit committee, compensation committee, and nominating and corporate governance committee. Mr. Heppell&#8217;s resignation as a director was to focus on other commitments and is not the result of any disagreement with Skye on any matter relating to Skye&#8217;s operations, policies or practices. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Additional Information and Where to Find It</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In connection with the proposed Arrangement, Skye will file a proxy statement on Schedule 14A containing important information about the proposed transaction and related matters. Additionally, EHT and Skye will file other relevant materials in connection with the proposed transaction with the applicable securities regulatory authorities. Investors and security holders of EHT and Skye are urged to carefully read the entire management information circular and proxy statement (including any amendments or supplements to such documents), respectively, when such documents become available before making any voting decision with respect to the proposed transaction because they will contain important information about the proposed transaction and the parties to the transaction. The EHT management information circular and the Skye proxy statement will be mailed to the EHT and Skye shareholders, respectively, as well as be accessible on the SEDAR and EDGAR profiles of the respective companies.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Investors and security holders of Skye will be able to obtain a free copy of the proxy statement, as well as other relevant filings containing information about Skye and the proposed transaction, including materials that will be incorporated by reference into the proxy statement, without charge, at the SEC&#8217;s website </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(www.sec.gov) or from Skye by contacting Skye&#8217;s Investor Relations at (858) 410-0266, by email at ir@skyebioscience.com, or by going to Skye&#8217;s Investor Relations page on its website at https://ir.skyebioscience.com and clicking on the link titled &#8220;SEC Filings.&#8221;</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">No Offer or Solicitation</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">This Current Report on Form 8-K does not constitute an offer to sell or the solicitation of an offer to buy any securities, or a solicitation of any vote or approval, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Participants in the Solicitation</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Skye and certain of their respective directors, executive officers and employees may be deemed to be participants in the solicitation of Skye proxies in respect of the proposed transaction. Information regarding the persons who may, under SEC rules, be deemed participants in the solicitation of proxies to Skye stockholders in connection with the proposed transaction will be set forth in the Skye proxy statement for the proposed transaction when available. Other information regarding the participants in the Skye proxy solicitation and a description of their direct and indirect interests in the proposed transaction, by security holdings or otherwise, will be contained in such proxy statement and other relevant materials to be filed with the SEC in connection with the proposed transaction. Copies of these documents may be obtained, free of charge, from the SEC or Skye as described in the preceding paragraph.</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 9.01 Financial Statements and Exhibits.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d) Exhibits</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:7.121%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.148%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:88.331%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit No.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Description</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="projectfran-ehtsupportagre.htm">EHT Support Agreement</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="projectfran-skyesupportagr.htm">Skye Support Agreement</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">104</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cover Page Interactive Data File (embedded within the inline XBRL document)</span></td></tr></table></div><div><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:0.75pt;padding-left:5.3pt"><span><br/></span></div><div style="padding-left:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.090%"><tr><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i1189c7fb5d1444d1abc194af3b75a3e5_10"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:49.941%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:47.859%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;SKYE BIOSCIENCE, INC.</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dated:  May 23, 2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">/s/&#160; Punit Dhillon</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Name: Punit Dhillon</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Title: Chief Executive Officer</span></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>projectfran-ehtsupportagre.htm
<DESCRIPTION>EX-10.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i6abf18a1fc584cf1b3660adeb9b083cc_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-top:24pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">SUPPORT AGREEMENT</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">THIS AGREEMENT is effective as of May 11, 2022.</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">BETWEEN&#58;</font></div><div style="margin-top:12pt;padding-left:72pt;padding-right:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">EMERALD HEALTH SCIENCES INC.,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> a corporation existing under the laws of the Province of British Columbia,</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Securityholder</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;)</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">AND&#58;</font></div><div style="margin-top:12pt;padding-left:72pt;padding-right:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">SKYE BIOSCIENCE, INC.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, a corporation existing under the laws of the State of Nevada,</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">SKYE</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;).</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">WHEREAS&#58;</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">A.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:25.31pt">Emerald Health Therapeutics, Inc. (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; or &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">EHT</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) and SKYE have entered into a definitive arrangement agreement (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Definitive Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) concurrent with the entering into of this Agreement providing for an arrangement of the Company pursuant to Section 288 of the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">Business Corporations Act </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(British Columbia) which will result, inter alia, in the acquisition by SKYE of all of the issued and outstanding shares in the capital of the Company in consideration for the issuance of shares of SKYE to shareholders of the Company pursuant to the terms thereof (the&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Transaction</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;)&#59;</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">B.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:25.92pt">The Securityholder or its affiliates (which includes for the purposes of this Agreement, any entity controlled by the Securityholder or an affiliate of any entity controlled by the Securityholder) beneficially own or have voting or dispositive power over the number of shares in the capital of the Company (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Shares</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) and other securities of EHT (including EHT Options and EHT Warrants), if any, set forth in Schedule A of this Agreement (the Shares and such other securities are collectively referred to herein as the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Securities</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;)&#59; and</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The Securityholder acknowledges that SKYE would not have entered into the Definitive Agreement but for the execution and delivery of this Agreement by the Securityholder. NOW THEREFORE THIS AGREEMENT WITNESSES that in consideration of the covenants and agreements herein contained, and other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the parties hereto agree as follows&#58;</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:27.75pt">Definitions.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> All terms used in this Agreement that are not defined herein and that are defined in the Definitive Agreement shall have the respective meanings ascribed to them in the Definitive Agreement. </font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:27.75pt">Representations of the Securityholder.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">  The Securityholder represents and warrants to SKYE that (and acknowledges that SKYE is relying upon such representations and warranties)&#58;</font></div><div style="margin-top:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">it or one of its affiliates is the sole registered owner and &#47; or beneficial owner of the Shares (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Owned Shares</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) and other Securities set forth in Schedule A of this Agreement (together with the Owned Shares, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Owned Securities</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) with good title thereto free of any and all encumbrances and demands of any nature or kind whatsoever&#59;</font></div><div style="margin-top:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">other than the Definitive Agreement, this Agreement and the clawback provisions of any relevant equity incentive plan of the Company, no person has any agreement or option, or any right or privilege, whether by law, pre-emptive or contractual, capable of becoming an agreement or option, for the exchange, acquisition or transfer from the Securityholder </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">328972.00001&#47;117300620.5</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">- 2 -</font></div></div><div style="margin-top:12pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">or any of its affiliates of any of the Owned Securities or any interest therein or right thereto&#59;</font></div><div style="margin-top:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">it or one of its affiliates has sole voting power and exclusive right of disposition with respect to the Owned Securities and sole power to agree to all matters set forth in this Agreement and neither the Securityholder nor any of its affiliates has previously granted or agreed to grant a proxy or other right to vote in respect of such Securities or entered into any voting trust, pooling or other agreement with respect to the right to vote, call meetings of securityholders or give consents or approvals of any kind as to such Securities except those which are no longer of force or effect&#59;</font></div><div style="margin-top:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">neither it nor any of its affiliates beneficially owns or controls any securities of the Company other than the Owned Securities&#59;</font></div><div style="margin-top:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">it has the legal capacity to execute and deliver this Agreement and to consummate the transactions contemplated hereby.  This Agreement has been duly executed and delivered by the Securityholder and, assuming the due authorization, execution and delivery by SKYE, this Agreement constitutes the legal, valid and binding obligation of the Securityholder, enforceable in accordance with its terms, subject to laws of general application and bankruptcy, insolvency and other similar laws affecting creditors&#8217; rights generally and general principles of equity&#59; and</font></div><div style="margin-top:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:25.02pt">except as may be set forth in the Definitive Agreement or as otherwise required by law (including, without limitation, filings as may be required under applicable securities laws), no filing with, and no permit, authorization, consent, or approval of, any Governmental Entity is necessary for the execution of this Agreement by the Securityholder and the performance by the Securityholder of its obligations under this Agreement, and none of the execution and delivery of this Agreement by the Securityholder, the performance by the Securityholder of its obligations under this Agreement or compliance by the Securityholder with any of the provisions of this Agreement shall (i) conflict with or result in any breach of the organizational documents, if applicable, of the Securityholder, (ii) result in a material violation or material breach of, or constitute (with or without notice or lapse of time, or both) a default (or give rise to any third party right of termination, cancellation, amendment, or acceleration) under any of the terms, conditions or provisions of any material note, bond, mortgage, indenture, license, contract, commitment, arrangement, understanding, agreement, or other instrument or obligation of any kind to which the Securityholder is a party, or (iii) violate any order, writ, injunction, decree, judgment, statute, rule, or regulation applicable to the Securityholder, except in each case under clauses (ii) and (iii), where the absence of filing or authorization, conflict, violation, breach, or default would not materially impair or materially adversely affect the ability of the Securityholder to perform the Securityholder's obligations hereunder on a timely basis.</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:27.75pt">Representations of SKYE.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">SKYE represents and warrants to the Securityholder that (and acknowledges that the Securityholder is relying upon such representations and warranties)&#58; </font></div><div style="margin-top:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">SKYE is, and will be as at the effective time of the Transaction, a company validly existing under the laws of the State of Nevada&#59; </font></div><div style="margin-top:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">it has the requisite corporate power and authority to enter into this Agreement and to perform its obligations hereunder&#59;</font></div><div style="margin-top:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">it has full power and authority to make, enter into and carry out the terms of this Agreement and the Definitive Agreement&#59;</font></div><div style="margin-top:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">this Agreement has been duly executed and delivered by SKYE and, assuming the due authorization, execution and delivery by the Securityholder, this Agreement constitutes the legal, valid and binding obligation of SKYE, enforceable in accordance with its </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">328972.00001&#47;117300620.5</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">- 3 -</font></div></div><div style="margin-top:12pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">terms, subject to laws of general application and bankruptcy, insolvency and other similar laws affecting creditors&#8217; rights generally and general principles of equity&#59; and</font></div><div style="margin-top:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">there are no legal proceedings in progress or pending before any Governmental Entity, or to the knowledge of SKYE, threatened against SKYE or its affiliates that would adversely affect in any manner the ability of SKYE to enter into this Agreement or the Definitive Agreement and to perform its obligations hereunder or thereunder.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">   </font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:27.75pt">Agreement to Vote Securities.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">  The Securityholder hereby agrees that at any meeting of the securityholders of the Company (or any class thereof), however called, or at any adjournment or postponement thereof, or in connection with any written consent of the securityholders of the Company (or any class thereof) or in any other circumstances upon which a vote, consent or other approval of all or some of the securityholders of the Company is sought (collectively, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Meeting</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), the Securityholder shall (or cause its affiliates or other holder of record to, if the Securityholder is the beneficial owner but not the holder of record of any of the Securities)&#58;</font></div><div style="margin-top:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">vote all the Owned Shares which it holds as of the record date for such Meeting in favour of the Transaction contemplated and any actions required in furtherance thereof or otherwise contemplated by the Definitive Agreement.  The Securityholder shall also cause such Shares to be counted as present for purposes of establishing a quorum at such Meeting&#59; and</font></div><div style="margin-top:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">vote all the Owned Shares which it holds as of the record date for such Meeting against the following actions (other than pursuant to the Transaction)&#58; (i) any Acquisition Proposal&#59; and&#47;or (ii) any other matter that would reasonably be regarded as being directed towards or likely to prevent, delay, impede or interfere with the consummation of the Transaction&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">and, no later than 10 days prior to any Meeting, each Securityholder will deliver or cause to be delivered (including by instructing the participant(s) in the book-based system operated by CDS Clearing and Depositary Services Inc. or other intermediary through which the Securityholder holds the Owned Shares to arrange for such delivery) to the Company&#8217;s transfer agent, or as otherwise directed by SKYE, a duly executed proxy (or other appropriate voting instrument) appointing as proxyholders those individuals designated by the Company in the information circular disseminated by the Company in connection with the Meeting, or such other individuals as SKYE may direct, and directing that the Owned Shares be voted at the Meeting in favour of the Transaction and all related matters, and thereafter not take any action to withdraw, amend or invalidate any such proxy (or other appropriate voting instrument) deposited by the Securityholder pursuant to this Agreement except in accordance with the terms hereof. </font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:27.75pt">No Voting Trusts.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">  The Securityholder will not, and will not permit any of its affiliates to, grant any proxies or powers of attorney, or any other authorization or consent with respect to any or all the Owned Shares or deposit any of the Owned Shares in a voting trust or subject any of such Securities to any arrangement or agreement with respect to the voting of such securities, other than agreements entered into with SKYE. </font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:27.75pt">Definition of Acquisition Proposal</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  For the purposes of this Agreement, &#8220;Acquisition Proposal&#8221; means, other than the transactions contemplated by the Definitive Agreement, the transactions comprising the EHT Realization Process and any transaction involving only EHT and&#47;or one or more of its wholly-owned Subsidiaries, any written or oral offer, proposal, expression of interest or inquiry to EHT or its shareholders from any person or group of persons (other than SKYE or any of its Subsidiaries) made after the date hereof relating to&#58; </font></div><div style="margin-top:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">any direct or indirect acquisition or sale (or lease, exchange, license, transfer or other arrangement having the same economic effect as a sale), whether in a single transaction or a series of related transactions, of&#58; (a) assets of EHT (including, without limitation, shares of one or more of its Subsidiaries) and&#47;or one or more of its Subsidiaries that, individually or in the aggregate, constitute 20% or more of the consolidated assets of </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">328972.00001&#47;117300620.5</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">- 4 -</font></div></div><div style="margin-top:12pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">EHT and its Subsidiaries or that contribute 20% or more of the consolidated revenue or net income of EHT and its Subsidiaries&#59; or (b) 20% or more of any class of outstanding voting or equity securities (or rights thereto) (and including securities convertible into or exercisable or exchangeable for voting or equity securities) of EHT&#59;</font></div><div style="margin-top:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">any direct or indirect take-over bid, issuer bid, tender offer, exchange offer, treasury issuance or other transaction that, if consummated, would result in a person or group of persons acquiring beneficial ownership of 20% or more of any class of voting or equity securities of EHT (and including securities convertible into or exercisable or exchangeable for voting or equity securities)&#59;</font></div><div style="margin-top:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">any plan of arrangement, merger, amalgamation, consolidation, share exchange, business combination, reorganization, recapitalization, joint venture, partnership, liquidation, dissolution or other similar transaction involving EHT or any one or more of its Subsidiaries that, individually or in the aggregate, constitute 20% or more of the consolidated assets of EHT and its Subsidiaries or that contribute 20% or more of the consolidated revenue of EHT and its Subsidiaries&#59; or</font></div><div style="margin-top:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">any other similar transactions involving EHT economically and functionally equivalent to the foregoing.</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">7.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:27.75pt">No Action to Reduce Likelihood of Success or Delay.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The Securityholder hereby agrees that it will not, and will not permit any of its affiliates to directly or indirectly, do or authorize or permit any of its Representatives to do, any of the following&#58;</font></div><div style="margin-top:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">solicit, initiate or knowingly encourage or otherwise facilitate any Acquisition Proposal or any inquiries, proposals or offers relating to any Acquisition Proposal or that could reasonably be expected to lead to an Acquisition Proposal&#59;</font></div><div style="margin-top:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">enter into, engage in, continue or otherwise participate in any discussions or negotiations with any person (other than SKYE) regarding any Acquisition Proposal or that could reasonably be expected to constitute or lead to an Acquisition Proposal&#59;</font></div><div style="margin-top:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">accept, approve, endorse or recommend, execute or enter into, or publicly propose to accept, approve, execute or enter into, any letter of intent, agreement in principle, agreement, arrangement, offer or understanding in respect of an Acquisition Proposal&#59;</font></div><div style="margin-top:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">furnish any information to any person in connection with a proposed Acquisition Proposal or otherwise assist, facilitate or encourage the making of, or cooperate in any way regarding, any Acquisition Proposal&#59;</font></div><div style="margin-top:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">solicit proxies or become a participant in a solicitation in opposition to or competition with SKYE in connection with the Transaction&#59; or</font></div><div style="margin-top:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:25.02pt">assist any person, entity or group in taking or planning any action that would compete with, restrain or otherwise serve to interfere with or inhibit SKYE in connection with the Transaction.</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">8.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:27.75pt">No Dissent.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">  The Securityholder hereby agrees that it will not, and it will not permit any of its affiliates to exercise any dissent rights in respect of the Transaction and the Securityholder hereby waives and shall cause its affiliates to waive any rights of appraisal or rights of dissent from the Transaction that the Securityholder or any of its affiliates may have.</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">9.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:27.75pt">Transfer and Encumbrance.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">  Except with the prior written consent of SKYE, the Securityholder and&#47;or any of its affiliates shall not&#58;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">328972.00001&#47;117300620.5</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">- 5 -</font></div></div><div style="margin-top:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">directly or indirectly sell, transfer, gift, assign or otherwise dispose of or exchange any or all of its Owned Securities or enter into any agreement, arrangement or understanding in connection therewith (whether by actual disposition, derivative transaction or effective economic disposition through cash settlement and including the deposit of any securities under a takeover bid or tender offer), provided that, the Securityholder may (i) exercise options, warrants or any other convertible security to acquire additional Shares&#59; (ii) transfer Owned Securities to its shareholders pursuant to a stock dividend, return of capital or other similar transaction (and, for greater certainty, any such Owned Securities so transferred will cease to be subject to this Agreement)&#59; and (iii) transfer Owned Securities to a corporation or other entity directly or indirectly owned or controlled by the Securityholder or under common control with or controlling the Securityholder provided that (A) such transfer to a corporation or other entity shall not relieve or release the Securityholder of or from its obligations under this Agreement, including, without limitation the obligation of the Securityholder to vote or cause to be voted all its Owned Securities in favour of the Transaction, (B) prompt written notice of such transfer is provided to SKYE, (C) the transferee agrees to be bound by the terms hereof pursuant to documentation approved in writing by SKYE in advance of such transfer and (D) the transferee continues to be a corporation or other entity directly or indirectly owned or controlled by the Securityholder or under common control with or controlling the Securityholder, at all times prior to the Effective Date and agrees that, if such transferee ceases to be so controlled, it will immediately transfer such Owned Securities back to the transferor&#59; </font></div><div style="margin-top:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">grant or enter into with any person any agreement or option, right or privilege (whether by law, pre-emptive or contractual) capable of becoming an agreement or option, for the exchange, acquisition or transfer from the Securityholder of any Owned Securities or any right or interest thereto&#59; or</font></div><div style="margin-top:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">allow any of its Owned Securities to become subject to any lien, pledge, mortgage, charge, restriction or security interest of any nature or kind whatsoever.</font></div><div style="padding-left:72pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">10.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.25pt">Additional Securities.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">  The Securityholder agrees that (a) any and all securities of the Company (collectively, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Additional Securities</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) which the Securityholder or any of its affiliates acquires beneficial ownership of, or direction or control over, after the execution of this Agreement (including pursuant to the exercise of options, warrants or other convertible securities) shall be subject to the terms of this Agreement to the same extent as if they constituted Securities held by the Securityholder as of the date of this Agreement and the terms &#8220;Shares&#8221;, &#8220;Securities&#8221;, &#8220;Owned Shares&#8221; and &#8220;Owned Securities&#8221; as used herein will include all such securities&#59; and (b) it will promptly notify SKYE of any Additional Securities acquired by it or any of its affiliates after the date of this Agreement.</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">11.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.25pt">Disclosure.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">  The Securityholder agrees to the details of this Agreement being set out in any press release, information circular, disclosure document or court documents produced by the Company or SKYE in connection with the Transaction and to this Agreement being made publicly available, including by filing on the System for Electronic Document Analysis and Retrieval (SEDAR) and the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR).</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Except as required by law or applicable stock exchange requirements or as otherwise permitted by this Agreement, the Securityholder agrees that it will not, and will ensure that its associates and affiliates do not, make any public announcement or public statements with respect to the transactions contemplated by this Agreement and the Definitive Agreement without the prior written approval of SKYE.</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">12.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.25pt">SKYE Acknowledgements.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">  SKYE agrees and acknowledges that the Securityholder is bound hereunder solely in his, her or its capacity as a securityholder of the Company and that the provisions of this Agreement shall not be deemed or interpreted to bind the Securityholder or any of its directors, officers or principal shareholder in his, her or its capacity as a director, officer or shareholder of the Company or any of its subsidiaries. For the avoidance of doubt, nothing in this Agreement shall limit or restrict any party from properly fulfilling his fiduciary duties as a </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">328972.00001&#47;117300620.5</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">- 6 -</font></div></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">director or officer of the Company. SKYE further acknowledges that the Securityholder shall not be considered part of the minority for the purposes of a majority of minority vote of the shareholders of the Company to approve the Arrangement for the purposes of Multilateral Instrument 61-101-</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">Protection of Minority Security Holders in Special Transactions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">13.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.25pt">Termination.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">  Unless otherwise provided for herein, this Agreement shall terminate on the earliest of&#58;</font></div><div style="margin-top:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">SKYE providing written notice of termination to the Securityholders&#59;</font></div><div style="margin-top:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">the termination of the Definitive Agreement in accordance with its terms&#59;</font></div><div style="margin-top:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">the effective time of the Transaction&#59; </font></div><div style="margin-top:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">SKYE, without the prior written consent of the Securityholder, decreasing the Share Consideration, and</font></div><div style="margin-top:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">SKYE, without the prior written consent of the Securityholder, changing the form of consideration set out in the Plan of Arrangement (other than to add additional consideration).</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">14.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.25pt">Effect of Termination.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">  If this Agreement is terminated in accordance with its terms, the provisions of this Agreement will become void and no party shall have liability to any other party, except in respect of a breach of this Agreement which occurred prior to such termination and the Securityholder shall be entitled to withdraw any form of proxy or power of attorney which it may have given with respect of the Shares. </font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">15.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.25pt">Specific Performance.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">  The Securityholder acknowledges that it will be impossible to measure in money the damage to SKYE if the Securityholder fails to comply with any of its obligations under this Agreement, that every such obligation is material and that, in the event of any such failure, SKYE will not have an adequate remedy at law or in damages and, accordingly, the Securityholder agrees that the issuance of an injunction or other equitable remedy is an appropriate remedy for any such failure. </font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">16.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.25pt">No Ownership Interest.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">  Nothing contained in this Agreement shall be deemed to vest in SKYE any direct or indirect ownership or incidence of ownership at law or in equity with respect to any of the Securities or any right or entitlement to acquire or become the owner at law or in equity of the Securities. Any rights, ownership and economic benefits of and relating to the Securities shall remain vested in and belong to the Securityholder and its affiliates, as the case may be. SKYE shall have no authority to manage, direct, superintend, restrict, regulate, govern or administer any of the policies or operations of the Company or exercise any power or authority to direct the Securityholder or his affiliates in the voting of any of the Securities, except as otherwise provided herein, or in the performance of the Securityholder&#8217;s and its affiliates&#8217; duties or responsibilities as a securityholder of the Company.  </font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">17.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.25pt">Successors and Assigns.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">  The provisions of this Agreement shall be binding upon and enure to the benefit of the parties hereto and their respective successors and permitted assigns, provided that no party may assign, delegate or otherwise transfer any of its or his rights, interests or obligations under this Agreement without the prior written consent of the other party. </font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">18.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.25pt">Entire Agreement.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">  This Agreement supersedes all prior agreements among the parties hereto with respect to the subject matter hereof and contains the entire agreement among the parties with respect to the subject matter hereof.  </font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">19.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.25pt">Amendments.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> This Agreement may not be modified or waived, except expressly by an instrument in writing signed by all the parties hereto.  </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">328972.00001&#47;117300620.5</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">- 7 -</font></div></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">20.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.25pt">No Waiver.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">  No waiver of any provision hereof by any party shall be deemed a waiver by any other party nor shall any such waiver be deemed a continuing waiver of any matter by such party.</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">21.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.25pt">Notice.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">  Any demand, notice or other communication to be given in connection with this Agreement must be given in writing and will be given by electronic means of communication addressed to the recipient as follows&#58; </font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:216pt;text-indent:-175.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">if to the Securityholder&#58;                         &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Email&#58; &#91;</font><font style="font-family:'Wingdings',sans-serif;font-size:11pt;font-weight:400;line-height:100%"></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#93;</font></div><div style="padding-left:216pt;text-indent:-175.5pt"><font><br></font></div><div style="padding-left:216pt;text-indent:-175.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160; </font></div><div style="padding-left:216pt;text-indent:-175.5pt"><font><br></font></div><div style="margin-top:12pt;padding-left:40.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">if to SKYE&#58;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Email&#58; &#91;</font><font style="font-family:'Wingdings',sans-serif;font-size:11pt;font-weight:400;line-height:100%"></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#93;</font></div><div style="margin-top:12pt;padding-left:40.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">with a copy to&#58;<br></font></div><div style="padding-left:40.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Fasken Martineau DuMoulin S.E.N.C.R.L., s.r.l.&#160;&#160;&#160;&#160;Email&#58; &#91;</font><font style="font-family:'Wingdings',sans-serif;font-size:11pt;font-weight:400;line-height:100%"></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#93;</font></div><div style="padding-left:22.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div><div style="padding-left:40.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Any</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">demand, notice or other communication given by electronic communication, on the day of transmittal thereof if given during the normal business hours of the recipient and on the business day during which such normal business hours next occur if not given during such hours on any day.</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">22.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.25pt">Further Assurances.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">  Each of the parties hereto agrees to execute such further and other deeds, documents and assurances and to do such further and other acts as may be necessary to carry out the true intent and meaning of this Agreement fully and effectually.</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">23.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.25pt">Severability.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">  Each of the covenants, provisions, sections, subsections and other subdivisions hereof is severable from every other covenant, provision, section, subsection and subdivision and the invalidity or unenforceability of any one or more covenants, provisions, sections, subsections and other subdivisions hereof shall not effect the validity or enforceability of the remaining covenants, provisions, sections, subsections or subdivisions hereof.</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">24.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.25pt">Miscellaneous.</font></div><div style="margin-top:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">This Agreement shall be construed in accordance with the laws of British Columbia and the parties hereto agree to attorn to the jurisdiction of the courts thereof.</font></div><div style="margin-top:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">This Agreement may be executed in one or more counterparts, each of which shall be deemed to be an original but all of which together shall constitute one and the same instrument.</font></div><div style="margin-top:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">All Section headings herein are for convenience of reference only and are not part of this Agreement and no construction or inference shall be derived therefrom.</font></div><div style="margin-top:12pt;padding-left:72pt;text-align:justify"><font><br></font></div><div style="margin-top:12pt;padding-left:36pt;padding-right:36pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">&#91;Remainder of the page intentionally left blank. Signature page follows.&#93;</font></div><div style="margin-top:12pt;padding-left:36pt;padding-right:36pt;text-align:center"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">328972.00001&#47;117300620.5</font></div></div></div><div id="i6abf18a1fc584cf1b3660adeb9b083cc_4"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">IN WITNESS WHEREOF, the parties have executed and delivered this Agreement as of the date first above written.</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">SKYE BIOSCIENCE, INC.<br></font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">per&#58;</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; Punit Dhillon</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><br>Authorized Signatory</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:46.153%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:24pt"><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">EMERALD HEALTH SCIENCES INC.<br></font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">per&#58;</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; Jim Heppell</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><br>Authorized Signatory</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:46.153%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:24pt"><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">&#91;Signature Page to EHT Support Agreement&#93;</font></div></div></div><div id="i6abf18a1fc584cf1b3660adeb9b083cc_7"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:24pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">SCHEDULE A<br>OWNERSHIP OF SECURITIES</font></div><div style="margin-top:12pt;text-align:center"><font><br></font></div><div style="padding-left:117.8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:49.679%"><tr><td style="width:1.0%"></td><td style="width:33.093%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.803%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.804%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:133%"><br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:133%">Number of Shares</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:133%"><br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:133%">Number of EHT Options</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:133%"><br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:133%">Number of EHT Warrants</font></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">39,401,608</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;</font></div></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">Nil</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">4,687,942</font></td></tr></table></div><div style="text-align:justify"><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">328972.00001&#47;117300620.5</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:42.948%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%">WSLEGAL&#92;085565&#92;00035&#92;30403240v4</font></div><div><font><br></font></div><div><font><br></font></div></td></tr></table></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.2
<SEQUENCE>3
<FILENAME>projectfran-skyesupportagr.htm
<DESCRIPTION>EX-10.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i830aa944dd8f47d198db390102e3221b_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Execution Version</font></div></div><div style="margin-top:24pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">SUPPORT AGREEMENT</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">THIS AGREEMENT is effective as of May 11, 2022.</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">BETWEEN&#58;</font></div><div style="margin-top:12pt;padding-left:72pt;padding-right:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">EMERALD HEALTH SCIENCES INC., </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">a corporation existing under the laws of the Province of British Columbia</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Securityholder</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;)</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">AND&#58;</font></div><div style="margin-top:12pt;padding-left:72pt;padding-right:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">EMERALD HEALTH THERAPEUTICS, INC.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, a corporation existing under the laws of the Province of British Columbia,</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">EHT</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;).</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">WHEREAS&#58;</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">A.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:25.31pt">Skye Bioscience, Inc. (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; or &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">SKYE</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) and EHT have entered into a definitive arrangement agreement (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Definitive Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) concurrent with the entering into of this Agreement providing for an arrangement of EHT pursuant to Section 288 of the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">Business Corporations Act </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(British Columbia) which will result, inter alia, in the acquisition by the Company of all of the issued and outstanding shares in the capital of EHT in consideration for the issuance of shares of the Company to shareholders of the EHT pursuant to the terms thereof (the&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Transaction</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;)&#59;</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">B.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:25.92pt">The Securityholder or its affiliates (which includes for the purposes of this Agreement, any entity controlled by the Securityholder or an affiliate of any entity controlled by the Securityholder) beneficially own or have voting or dispositive power over the number of shares in the capital of the Company (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Shares</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) and other securities of SKYE (including SKYE Options, SKYE Warrants, SKYE RSUs, and other convertible debt), if any, set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Schedule A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> of this Agreement (the Shares and such other securities are collectively referred to herein as the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Securities</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;)&#59; and</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">C.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:25.92pt">The Securityholder acknowledges that EHT would not enter into the Definitive Agreement but for the execution and delivery of this Agreement by the Securityholder.</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">NOW THEREFORE THIS AGREEMENT WITNESSES that in consideration of the covenants and agreements herein contained, and other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the parties hereto agree as follows&#58;</font></div><div id="i830aa944dd8f47d198db390102e3221b_4"></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:27.75pt">Definitions.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> All terms used in this Agreement that are not defined herein and that are defined in the Definitive Agreement shall have the respective meanings ascribed to them in the Definitive Agreement. The term &#8220;beneficially owns&#8221; or &#8220;beneficial owner&#8221; has the meaning assigned to such term in Rule 13d-3 under the Securities Exchange Act of 1934, as amended.</font></div><div id="i830aa944dd8f47d198db390102e3221b_7"></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:27.75pt">Representations of the Securityholder.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">  The Securityholder represents and warrants to EHT that (and acknowledges that EHT is relying upon such representations and warranties)&#58;</font></div><div id="i830aa944dd8f47d198db390102e3221b_10"></div><div style="margin-top:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">it or one of its affiliates is the sole registered owner and &#47; or beneficial owner of the Shares (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Owned Shares</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) and other Securities set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Schedule A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> of this Agreement (together with the Owned Shares, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Owned Securities</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) with good title thereto free of any and all encumbrances and demands of any nature or kind whatsoever&#59;</font></div><div id="i830aa944dd8f47d198db390102e3221b_13"></div><div style="margin-top:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">other than the Definitive Agreement, this Agreement and the clawback provisions of any relevant equity incentive plan of the Company, no person has any agreement or option, or </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">328972.00001&#47;116955760.3</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:42.948%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SF-4826580.3 </font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">- 2 -</font></div></div><div style="margin-top:12pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">any right or privilege, whether by law, pre-emptive or contractual, capable of becoming an agreement or option, for the exchange, acquisition or transfer from the Securityholder or any of its affiliates of any of the Owned Securities or any interest therein or right thereto&#59;</font></div><div id="i830aa944dd8f47d198db390102e3221b_16"></div><div style="margin-top:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">it or one of its affiliates has sole voting power and exclusive right of disposition with respect to the Owned Securities and sole power to agree to all matters set forth in this Agreement and neither the Securityholder nor any of its affiliates has previously granted or agreed to grant a proxy or other right to vote in respect of such Securities or entered into any voting trust, pooling or other agreement with respect to the right to vote, call meetings of securityholders or give consents or approvals of any kind as to such Securities except those which are no longer of force or effect&#59;</font></div><div id="i830aa944dd8f47d198db390102e3221b_19"></div><div style="margin-top:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">neither it nor any of its affiliates beneficially owns or controls any securities of the Company other than the Owned Securities&#59;</font></div><div id="i830aa944dd8f47d198db390102e3221b_22"></div><div style="margin-top:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">it has the legal capacity to execute and deliver this Agreement and to consummate the transactions contemplated hereby.  This Agreement has been duly executed and delivered by the Securityholder and, assuming the due authorization, execution and delivery by EHT, this Agreement constitutes the legal, valid and binding obligation of the Securityholder, enforceable in accordance with its terms, subject to laws of general application and bankruptcy, insolvency and other similar laws affecting creditors&#8217; rights generally and general principles of equity&#59; and</font></div><div id="i830aa944dd8f47d198db390102e3221b_25"></div><div style="margin-top:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:25.02pt">except as may be set forth in the Definitive Agreement or as otherwise required by law (including, without limitation, filings as may be required under applicable securities laws), no filing with, and no permit, authorization, consent, or approval of, any Governmental Entity is necessary for the execution of this Agreement by the Securityholder and the performance by the Securityholder of its obligations under this Agreement, and none of the execution and delivery of this Agreement by the Securityholder, the performance by the Securityholder of its obligations under this Agreement or compliance by the Securityholder with any of the provisions of this Agreement shall (i) conflict with or result in any breach of the organizational documents, if applicable, of the Securityholder, (ii) result in a material violation or material breach of, or constitute (with or without notice or lapse of time, or both) a default (or give rise to any third party right of termination, cancellation, amendment, or acceleration) under any of the terms, conditions or provisions of any material note, bond, mortgage, indenture, license, contract, commitment, arrangement, understanding, agreement, or other instrument or obligation of any kind to which the Securityholder is a party, or (iii) violate any order, writ, injunction, decree, judgment, statute, rule, or regulation applicable to the Securityholder, except in each case under clauses (ii) and (iii), where the absence of filing or authorization, conflict, violation, breach, or default would not materially impair or materially adversely affect the ability of the Securityholder to perform the Securityholder's obligations hereunder on a timely basis.</font></div><div id="i830aa944dd8f47d198db390102e3221b_28"></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:27.75pt">Representations of EHT.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">EHT represents and warrants to the Securityholder that (and acknowledges that the Securityholder is relying upon such representations and warranties)&#58; </font></div><div id="i830aa944dd8f47d198db390102e3221b_31"></div><div style="margin-top:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">EHT is, and will be as at the effective time of the Transaction, a company validly existing under the laws of the Province of British Columbia&#59; </font></div><div id="i830aa944dd8f47d198db390102e3221b_34"></div><div style="margin-top:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">it has the requisite corporate power and authority to enter into this Agreement and to perform its obligations hereunder&#59;</font></div><div id="i830aa944dd8f47d198db390102e3221b_37"></div><div style="margin-top:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">it has full power and authority to make, enter into and carry out the terms of this Agreement and the Definitive Agreement&#59;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:42.948%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SF-4826580.3 </font></div></td></tr></table></div></div></div><div id="i830aa944dd8f47d198db390102e3221b_40"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Execution Version</font></div></div><div style="margin-top:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">this Agreement has been duly executed and delivered by EHT and, assuming the due authorization, execution and delivery by the Securityholder, this Agreement constitutes the legal, valid and binding obligation of EHT, enforceable in accordance with its terms, subject to laws of general application and bankruptcy, insolvency and other similar laws affecting creditors&#8217; rights generally and general principles of equity&#59; and</font></div><div id="i830aa944dd8f47d198db390102e3221b_43"></div><div style="margin-top:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">there are no legal proceedings in progress or pending before any Governmental Entity, or to the knowledge of EHT, threatened against EHT or its affiliates that would adversely affect in any manner the ability of EHT to enter into this Agreement or the Definitive Agreement and to perform its obligations hereunder or thereunder.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">   </font></div><div id="i830aa944dd8f47d198db390102e3221b_46"></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:27.75pt">Agreement to Vote Securities.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">  The Securityholder hereby agrees that at any meeting of the securityholders of the Company (or any class thereof), however called, or at any adjournment or postponement thereof, or in connection with any written consent of the securityholders of the Company (or any class thereof) or in any other circumstances upon which a vote, consent or other approval of all or some of the securityholders of the Company is sought (collectively, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Meeting</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), the Securityholder shall (or cause its affiliates or other holder of record to, if the Securityholder is the beneficial owner but not the holder of record of any of the Securities)&#58;</font></div><div id="i830aa944dd8f47d198db390102e3221b_49"></div><div style="margin-top:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">vote all the Owned Shares which it holds as of the record date for such Meeting in favour of the Transaction contemplated and any actions required in furtherance thereof or otherwise contemplated by the Definitive Agreement.  The Securityholder shall also cause such Shares to be counted as present for purposes of establishing a quorum at such Meeting&#59; and</font></div><div id="i830aa944dd8f47d198db390102e3221b_52"></div><div style="margin-top:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">vote all the Owned Shares which it holds as of the record date for such Meeting against the following actions (other than pursuant to the Transaction)&#58; (i) any Acquisition Proposal&#59; and&#47;or (ii) any other matter that would reasonably be regarded as being directed towards or likely to prevent, delay, impede or interfere with the consummation of the Transaction&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">and, no later than 10 days prior to any Meeting, each Securityholder will deliver or cause to be delivered (including by instructing any intermediary through which the Securityholder holds the Owned Shares to arrange for such delivery) to the Company&#8217;s transfer agent, or as otherwise directed by EHT, a duly executed proxy (or other appropriate voting instrument) appointing as proxyholders those individuals designated by the Company in the proxy statement disseminated by the Company in connection with the Meeting, or such other individuals as EHT may direct, and directing that the Owned Shares be voted at the Meeting in favour of the Transaction and all related matters, and thereafter not take any action to withdraw, amend or invalidate any such proxy (or other appropriate voting instrument) deposited by the Securityholder pursuant to this Agreement except in accordance with the terms hereof. </font></div><div id="i830aa944dd8f47d198db390102e3221b_55"></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Notwithstanding the foregoing, EHT and SKYE acknowledge and agree that the Securityholder&#8217;s votes shall not be counted for purposes of satisfying the closing condition in the Definitive Agreement related to obtaining the majority approval of the disinterested SKYE Shareholders (as defined therein).</font></div><div id="i830aa944dd8f47d198db390102e3221b_58"></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:27.75pt">No Voting Trusts.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">  The Securityholder will not, and will not permit any of its affiliates to, grant any proxies or powers of attorney, or any other authorization or consent with respect to any or all the Owned Shares or deposit any of the Owned Shares in a voting trust or subject any of such Securities to any arrangement or agreement with respect to the voting of such securities, other than agreements entered into with EHT. </font></div><div id="i830aa944dd8f47d198db390102e3221b_61"></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:27.75pt">Definition of Acquisition Proposal</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  For the purposes of this Agreement, &#8220;Acquisition Proposal&#8221; means, other than the transactions contemplated by the Definitive Agreement, the transactions comprising the EHT Realization Process and any transaction involving only EHT and&#47;or one or more of its wholly-owned Subsidiaries, any written or oral offer, proposal, expression of interest </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">328972.00001&#47;116955760.3</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:42.948%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SF-4826580.3 </font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">- 4 -</font></div></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">or inquiry to SKYE or its shareholders from any person or group of persons (other than EHT or any of its Subsidiaries) made after the date hereof relating to&#58; </font></div><div id="i830aa944dd8f47d198db390102e3221b_64"></div><div style="margin-top:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">any direct or indirect acquisition or sale (or lease, exchange, license, transfer or other arrangement having the same economic effect as a sale), whether in a single transaction or a series of related transactions, of&#58; (a) assets of SKYE (including, without limitation, shares of one or more of its Subsidiaries) and&#47;or one or more of its Subsidiaries that, individually or in the aggregate, constitute 20% or more of the consolidated assets of SKYE and its Subsidiaries or that contribute 20% or more of the consolidated revenue or net income of SKYE and its Subsidiaries&#59; or (b) 20% or more of any class of outstanding voting or equity securities (or rights thereto) (and including securities convertible into or exercisable or exchangeable for voting or equity securities) of SKYE&#59;</font></div><div id="i830aa944dd8f47d198db390102e3221b_67"></div><div style="margin-top:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">any direct or indirect take-over bid, issuer bid, tender offer, exchange offer, treasury issuance or other transaction that, if consummated, would result in a person or group of persons acquiring beneficial ownership of 20% or more of any class of voting or equity securities of SKYE (and including securities convertible into or exercisable or exchangeable for voting or equity securities)&#59;</font></div><div id="i830aa944dd8f47d198db390102e3221b_70"></div><div style="margin-top:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">any plan of arrangement, merger, amalgamation, consolidation, share exchange, business combination, reorganization, recapitalization, joint venture, partnership, liquidation, dissolution or other similar transaction involving SKYE or any one or more of its Subsidiaries that, individually or in the aggregate, constitute 20% or more of the consolidated assets of SKYE and its Subsidiaries or that contribute 20% or more of the consolidated revenue of SKYE and its Subsidiaries&#59; or</font></div><div id="i830aa944dd8f47d198db390102e3221b_73"></div><div style="margin-top:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">any other similar transactions involving SKYE economically and functionally equivalent to the foregoing.</font></div><div id="i830aa944dd8f47d198db390102e3221b_76"></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">7.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:27.75pt">No Action to Reduce Likelihood of Success or Delay.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The Securityholder hereby agrees that it will not, and will not permit any of its affiliates to directly or indirectly, do or authorize or permit any of its Representatives to do, any of the following&#58;</font></div><div id="i830aa944dd8f47d198db390102e3221b_79"></div><div style="margin-top:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">solicit, initiate or knowingly encourage or otherwise facilitate any Acquisition Proposal or any inquiries, proposals or offers relating to any Acquisition Proposal or that could reasonably be expected to lead to an Acquisition Proposal&#59;</font></div><div id="i830aa944dd8f47d198db390102e3221b_82"></div><div style="margin-top:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">enter into, engage in, continue or otherwise participate in any discussions or negotiations with any person (other than EHT) regarding any Acquisition Proposal or that could reasonably be expected to constitute or lead to an Acquisition Proposal&#59;</font></div><div id="i830aa944dd8f47d198db390102e3221b_85"></div><div style="margin-top:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">accept, approve, endorse or recommend, execute or enter into, or publicly propose to accept, approve, execute or enter into, any letter of intent, agreement in principle, agreement, arrangement, offer or understanding in respect of an Acquisition Proposal&#59;</font></div><div id="i830aa944dd8f47d198db390102e3221b_88"></div><div style="margin-top:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">furnish any information to any person in connection with a proposed Acquisition Proposal or otherwise assist, facilitate or encourage the making of, or cooperate in any way regarding, any Acquisition Proposal&#59;</font></div><div id="i830aa944dd8f47d198db390102e3221b_91"></div><div style="margin-top:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">solicit proxies or become a participant in a solicitation in opposition to or competition with EHT in connection with the Transaction&#59; or</font></div><div id="i830aa944dd8f47d198db390102e3221b_94"></div><div style="margin-top:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:25.02pt">assist any person, entity or group in taking or planning any action that would compete with, restrain or otherwise serve to interfere with or inhibit EHT in connection with the Transaction.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:42.948%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SF-4826580.3 </font></div></td></tr></table></div></div></div><div id="i830aa944dd8f47d198db390102e3221b_97"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Execution Version</font></div></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">8.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:27.75pt">No Dissent.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> If applicable, the Securityholder hereby agrees that it will not, and it will not permit any of its affiliates to exercise any dissent rights in respect of the Transaction and the Securityholder hereby waives and shall cause its affiliates to waive any rights of appraisal or rights of dissent from the Transaction that the Securityholder or any of its affiliates may have.</font></div><div id="i830aa944dd8f47d198db390102e3221b_100"></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">9.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:27.75pt">Transfer and Encumbrance.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">  Except with the prior written consent of EHT, the Securityholder and&#47;or any of its affiliates shall not&#58;</font></div><div id="i830aa944dd8f47d198db390102e3221b_103"></div><div style="margin-top:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">directly or indirectly sell, transfer, gift, assign or otherwise dispose of or exchange any or all of its Owned Securities or enter into any agreement, arrangement or understanding in connection therewith (whether by actual disposition, derivative transaction or effective economic disposition through cash settlement and including the deposit of any securities under a takeover bid or tender offer), provided that, the Securityholder may (i) exercise options, warrants or any other convertible security to acquire additional Shares&#59; (ii) transfer Owned Securities to its shareholders pursuant to a stock dividend, return of capital or other similar transaction (and for greater certainty, any such Owned Securities so transferred will cease to be subject to this Agreement)&#59; and (iii) transfer Owned Securities to a corporation or other entity directly or indirectly owned or controlled by the Securityholder or under common control with or controlling the Securityholder provided that (A) such transfer to a corporation or other entity shall not relieve or release the Securityholder of or from its obligations under this Agreement, including, without limitation the obligation of the Securityholder to vote or cause to be voted all its Owned Securities in favour of the Transaction, (B) prompt written notice of such transfer is provided to EHT, (C) the transferee agrees to be bound by the terms hereof pursuant to documentation approved in writing by EHT in advance of such transfer and (D) the transferee continues to be a corporation or other entity directly or indirectly owned or controlled by the Securityholder or under common control with or controlling the Securityholder, at all times prior to the Effective Date and agrees that, if such transferee ceases to be so controlled, it will immediately transfer such Owned Securities back to the transferor&#59; </font></div><div id="i830aa944dd8f47d198db390102e3221b_106"></div><div style="margin-top:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">grant or enter into with any person any agreement or option, right or privilege (whether by law, pre-emptive or contractual) capable of becoming an agreement or option, for the exchange, acquisition or transfer from the Securityholder of any Owned Securities or any right or interest thereto&#59; or</font></div><div id="i830aa944dd8f47d198db390102e3221b_109"></div><div style="margin-top:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">allow any of its Owned Securities to become subject to any lien, pledge, mortgage, charge, restriction or security interest of any nature or kind whatsoever .</font></div><div style="margin-top:12pt;padding-left:72pt;text-align:justify"><font><br></font></div><div id="i830aa944dd8f47d198db390102e3221b_112"></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">10.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.25pt">Additional Securities.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">  The Securityholder agrees that (a) any and all securities of the Company (collectively, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Additional Securities</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) which the Securityholder or any of its affiliates acquires beneficial ownership of, or direction or control over, after the execution of this Agreement (including pursuant to the exercise of options, warrants or other convertible securities) shall be subject to the terms of this Agreement to the same extent as if they constituted Securities held by the Securityholder as of the date of this Agreement and the terms &#8220;Shares&#8221;, &#8220;Securities&#8221;, &#8220;Owned Shares&#8221; and &#8220;Owned Securities&#8221; as used herein will include all such securities&#59; and (b) it will promptly notify EHT of any Additional Securities acquired by it or any of its affiliates after the date of this Agreement.</font></div><div id="i830aa944dd8f47d198db390102e3221b_115"></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">11.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.25pt">Disclosure.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">  The Securityholder agrees to the details of this Agreement being set out in any press release, information circular, proxy statement, disclosure document or court documents produced by the Company or EHT in connection with the Transaction and to this Agreement being made publicly available, including by filing on the System for Electronic Document Analysis and Retrieval (SEDAR) and the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR).</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Except as required by law or applicable stock exchange requirements or as otherwise permitted by this Agreement, the Securityholder agrees that it will not, and will ensure that its associates </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">328972.00001&#47;116955760.3</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:42.948%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SF-4826580.3 </font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">- 6 -</font></div></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">and affiliates do not, make any public announcement or public statements with respect to the transactions contemplated by this Agreement and the Definitive Agreement without the prior written approval of EHT.</font></div><div id="i830aa944dd8f47d198db390102e3221b_118"></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">12.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.25pt">EHT Acknowledgements.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">  EHT agrees and acknowledges that the Securityholder is bound hereunder solely in his, her or its capacity as a securityholder of the Company and that the provisions of this Agreement shall not be deemed or interpreted to bind the Securityholder or any of its directors, officers or principal shareholder in his, her or its capacity as a director, officer or shareholder of the Company or any of its subsidiaries. For the avoidance of doubt, nothing in this Agreement shall limit or restrict any party from properly fulfilling his fiduciary duties as a director or officer of the Company.</font></div><div id="i830aa944dd8f47d198db390102e3221b_121"></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">13.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.25pt">Termination.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">  Unless otherwise provided for herein, this Agreement shall terminate on the earliest of&#58;</font></div><div id="i830aa944dd8f47d198db390102e3221b_124"></div><div style="margin-top:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">EHT providing written notice of termination to the Securityholders&#59;</font></div><div id="i830aa944dd8f47d198db390102e3221b_127"></div><div style="margin-top:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">the termination of the Definitive Agreement in accordance with its terms&#59; </font></div><div id="i830aa944dd8f47d198db390102e3221b_130"></div><div style="margin-top:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">the effective time of the Transaction&#59;</font></div><div id="i830aa944dd8f47d198db390102e3221b_133"></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">EHT, without the prior written consent of the Securityholder, decreasing the Share Consideration, and</font></div><div id="i830aa944dd8f47d198db390102e3221b_136"></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">EHT, without the prior written consent of the Securityholder, changing the form of consideration set out in the Plan of Arrangement (other than to add additional consideration).</font></div><div id="i830aa944dd8f47d198db390102e3221b_139"></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">14.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.25pt">Effect of Termination.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">  If this Agreement is terminated in accordance with its terms, the provisions of this Agreement will become void and no party shall have liability to any other party, except in respect of a breach of this Agreement which occurred prior to such termination and the Securityholder shall be entitled to withdraw any form of proxy or power of attorney which it may have given with respect of the Shares. </font></div><div id="i830aa944dd8f47d198db390102e3221b_142"></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">15.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.25pt">Specific Performance.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">  The Securityholder acknowledges that it will be impossible to measure in money the damage to EHT if the Securityholder fails to comply with any of its obligations under this Agreement, that every such obligation is material and that, in the event of any such failure, EHT will not have an adequate remedy at law or in damages and, accordingly, the Securityholder agrees that the issuance of an injunction or other equitable remedy is an appropriate remedy for any such failure. </font></div><div id="i830aa944dd8f47d198db390102e3221b_145"></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">16.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.25pt">No Ownership Interest.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">  Nothing contained in this Agreement shall be deemed to vest in EHT any direct or indirect ownership or incidence of ownership at law or in equity with respect to any of the Securities or any right or entitlement to acquire or become the owner at law or in equity of the Securities. Any rights, ownership and economic benefits of and relating to the Securities shall remain vested in and belong to the Securityholder and its affiliates, as the case may be. EHT shall have no authority to manage, direct, superintend, restrict, regulate, govern or administer any of the policies or operations of the Company or exercise any power or authority to direct the Securityholder or his affiliates in the voting of any of the Securities, except as otherwise provided herein, or in the performance of the Securityholder&#8217;s and its affiliates&#8217; duties or responsibilities as a securityholder of the Company.  </font></div><div id="i830aa944dd8f47d198db390102e3221b_148"></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">17.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.25pt">Successors and Assigns.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">  The provisions of this Agreement shall be binding upon and enure to the benefit of the parties hereto and their respective successors and permitted assigns, provided that no party may assign, delegate or otherwise transfer any of its or his rights, interests or obligations under this Agreement without the prior written consent of the other party. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:42.948%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SF-4826580.3 </font></div></td></tr></table></div></div></div><div id="i830aa944dd8f47d198db390102e3221b_151"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Execution Version</font></div></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">18.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.25pt">Entire Agreement.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">  This Agreement supersedes all prior agreements among the parties hereto with respect to the subject matter hereof and contains the entire agreement among the parties with respect to the subject matter hereof.  </font></div><div id="i830aa944dd8f47d198db390102e3221b_154"></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">19.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.25pt">Amendments.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> This Agreement may not be modified or waived, except expressly by an instrument in writing signed by all the parties hereto.  </font></div><div id="i830aa944dd8f47d198db390102e3221b_157"></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">20.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.25pt">No Waiver.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">  No waiver of any provision hereof by any party shall be deemed a waiver by any other party nor shall any such waiver be deemed a continuing waiver of any matter by such party.</font></div><div id="i830aa944dd8f47d198db390102e3221b_160"></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">21.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.25pt">Notice.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">  Any demand, notice or other communication to be given in connection with this Agreement must be given in writing and will be given by electronic means of communication addressed to the recipient as follows&#58; </font></div><div style="margin-top:12pt;padding-left:216pt;text-indent:-175.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">if to the Securityholder&#58;&#160;&#160;&#160;&#160;Email&#58; &#91;</font><font style="font-family:'Wingdings',sans-serif;font-size:11pt;font-weight:400;line-height:100%"></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#93;</font></div><div style="margin-top:12pt;padding-left:40.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">if to EHT&#58;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Emerald Health Therapeutics, Inc. </font></div><div style="padding-left:144pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4226 Commerce Circle, Unit 101</font></div><div style="padding-left:144pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Victoria, BC V8Z 6N6</font></div><div style="padding-left:180pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Attn&#58; Mohammed Jiwan, Chief Operating Officer</font></div><div style="padding-left:180pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Email&#58; &#91;</font><font style="font-family:'Wingdings',sans-serif;font-size:11pt;font-weight:400;line-height:100%"></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#93;</font></div><div style="margin-top:12pt;padding-left:40.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">with a copy to&#58;<br></font></div><div style="padding-left:40.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Fasken Martineau DuMoulin S.E.N.C.R.L., s.r.l.&#58;</font></div><div style="padding-left:40.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div><div style="padding-left:180pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">800 Victoria Square, Suite 3500 </font></div><div style="padding-left:180pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">P.O. Box 242</font></div><div style="padding-left:180pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Montr&#233;al, Quebec  </font></div><div style="padding-left:180pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Canada, H4Z 1E9<br>&#160;&#160;&#160;&#160;Attention&#58; Neil Kravitz<br>&#160;&#160;&#160;&#160;Fax Number&#58;  (514) 397.7600</font></div><div style="padding-left:22.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Email&#58;&#91;</font><font style="font-family:'Wingdings',sans-serif;font-size:11pt;font-weight:400;line-height:100%"></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#93;</font></div><div style="padding-left:22.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;and to&#58; </font></div><div style="padding-left:22.3pt"><font><br></font></div><div style="padding-left:22.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Bennett Jones LLP&#58;</font></div><div style="padding-left:40.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2500 Park Place</font></div><div style="padding-left:180pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">666 Burrard Street</font></div><div style="padding-left:180pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Vancouver, B.C.</font></div><div style="padding-left:180pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Canada, V6C 2X8</font></div><div style="padding-left:180pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Attention&#58; James D. Beeby<br>&#160;&#160;&#160;&#160;Fax Number&#58;  (604) 891.5100</font></div><div style="padding-left:22.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Email&#58; &#91;</font><font style="font-family:'Wingdings',sans-serif;font-size:11pt;font-weight:400;line-height:100%"></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#93;</font></div><div style="padding-left:22.3pt"><font><br></font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Any</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">demand, notice or other communication given by electronic communication, on the day of transmittal thereof if given during the normal business hours of the recipient and on the business day during which such normal business hours next occur if not given during such hours on any day.</font></div><div id="i830aa944dd8f47d198db390102e3221b_163"></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">22.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.25pt">Further Assurances.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">  Each of the parties hereto agrees to execute such further and other deeds, documents and assurances and to do such further and other acts as may be necessary to carry out the true intent and meaning of this Agreement fully and effectually.</font></div><div id="i830aa944dd8f47d198db390102e3221b_166"></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">23.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.25pt">Severability.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">  Each of the covenants, provisions, sections, subsections and other subdivisions hereof is severable from every other covenant, provision, section, subsection and subdivision and the invalidity or unenforceability of any one or more covenants, provisions, sections, subsections </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">328972.00001&#47;116955760.3</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:42.948%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SF-4826580.3 </font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">- 8 -</font></div></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">and other subdivisions hereof shall not effect the validity or enforceability of the remaining covenants, provisions, sections, subsections or subdivisions hereof.</font></div><div id="i830aa944dd8f47d198db390102e3221b_169"></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">24.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.25pt">Miscellaneous.</font></div><div id="i830aa944dd8f47d198db390102e3221b_172"></div><div style="margin-top:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">This Agreement shall be construed in accordance with the State of Nevada and the federal laws of the United States applicable therein without giving effect to any choice or conflict of law provision or rule that would cause the application of  laws of any jurisdiction other than the State of Nevada and the parties hereto agree to attorn to the jurisdiction of the courts thereof.</font></div><div id="i830aa944dd8f47d198db390102e3221b_175"></div><div style="margin-top:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">This Agreement may be executed in one or more counterparts, each of which shall be deemed to be an original but all of which together shall constitute one and the same instrument.</font></div><div id="i830aa944dd8f47d198db390102e3221b_178"></div><div style="margin-top:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">All Section headings herein are for convenience of reference only and are not part of this Agreement and no construction or inference shall be derived therefrom.</font></div><div style="margin-top:12pt;padding-left:72pt;text-align:justify"><font><br></font></div><div style="margin-top:12pt;padding-left:36pt;padding-right:36pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">&#91;Remainder of the page intentionally left blank. Signature page follows.&#93;</font></div><div style="margin-top:12pt;padding-left:36pt;padding-right:36pt;text-align:center"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:42.948%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SF-4826580.3 </font></div></td></tr></table></div></div></div><div id="i830aa944dd8f47d198db390102e3221b_181"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Execution Version</font></div></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">IN WITNESS WHEREOF, the parties have executed and delivered this Agreement as of the date first above written.</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">EMERALD HEALTH THERAPEUTICS, INC.<br></font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">per&#58;</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; Mohammed Jiwan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><br>Authorized Signatory</font></div><div style="margin-top:12pt;text-align:justify"><font><br></font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">EMERALD HEALTH SCIENCES INC.<br></font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">per&#58;</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; Jim Heppell</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><br>Authorized Signatory</font></div><div style="margin-top:12pt;text-align:justify"><font><br></font></div><div style="margin-top:12pt;text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">&#91;Signature Page to SKYE Support Agreement&#93;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:42.948%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SF-4826580.3 </font></div></td></tr></table></div></div></div><div id="i830aa944dd8f47d198db390102e3221b_184"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:24pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">SCHEDULE A<br>OWNERSHIP OF SECURITIES</font></div><div style="margin-top:12pt;text-align:center"><font><br></font></div><div style="padding-left:36.82pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:84.775%"><tr><td style="width:1.0%"></td><td style="width:19.315%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.803%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.181%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.803%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.398%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:133%"><br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:133%">Number of Shares</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:133%"><br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:133%">Number of SKYE Options</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:133%">Number of SKYE RSUs</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:133%"><br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:133%">Number of SKYE Warrants</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:133%"><br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:133%">Convertible Debt</font></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">111,387,251</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">None.</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">None.</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">7,500,000</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">5,521,968</font></td></tr></table></div><div style="text-align:justify"><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:42.948%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SF-4826580.3 </font></div></td></tr></table></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>4
<FILENAME>skye-20220518.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:dc1fbabb-1639-4b5a-baab-8e85f16f98d4,g:97730539-3d09-442b-b5a0-dc05c4ac6ccc-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:skye="http://skyebioscience.com/20220518" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://skyebioscience.com/20220518">
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2021" schemaLocation="https://xbrl.sec.gov/dei/2021/dei-2021.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="skye-20220518_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="skye-20220518_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="CoverPage" roleURI="http://skyebioscience.com/role/CoverPage">
        <link:definition>0001001 - Document - Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>5
<FILENAME>skye-20220518_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:dc1fbabb-1639-4b5a-baab-8e85f16f98d4,g:97730539-3d09-442b-b5a0-dc05c4ac6ccc-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_dei_PreCommencementTenderOffer_410693ca-ec74-4ae0-acbe-eaa6769a4afe_terseLabel_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementTenderOffer" xlink:to="lab_dei_PreCommencementTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_262014df-902c-4881-88b9-226a21c12c2b_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_96624879-4266-4e9a-bce7-16db4ac453e0_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_f5e57b3c-4a0b-48cc-bca3-8f4a840edbc1_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_2bd94f85-2906-4f79-8a0e-b6675c11a0d6_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_WrittenCommunications_3afbd3c3-e271-441b-96ed-c9ae9303dc4a_terseLabel_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Written Communications</link:label>
    <link:label id="lab_dei_WrittenCommunications_label_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Written Communications</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_WrittenCommunications"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_WrittenCommunications" xlink:to="lab_dei_WrittenCommunications" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_08dd0c28-ac3b-4980-a289-2cbb87040ebc_terseLabel_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementIssuerTenderOffer" xlink:to="lab_dei_PreCommencementIssuerTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_96252ee8-99a6-4e31-ae60-374b1f02d484_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_9a510ebc-c0c5-4ab1-ad3f-f41b72b5f024_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SolicitingMaterial_76947f65-8245-4ff5-9570-0a13a114152d_terseLabel_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Soliciting Material</link:label>
    <link:label id="lab_dei_SolicitingMaterial_label_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Soliciting Material</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SolicitingMaterial"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SolicitingMaterial" xlink:to="lab_dei_SolicitingMaterial" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_ea3752b5-ba98-4b48-aaff-a95fbc36ca92_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_4e50540d-ea0a-442d-9ad9-59676d20c311_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_28fc8632-0780-4117-8f8e-0c18c26e99d7_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_88dbad98-577c-4126-8599-73b424b64c5b_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_61e57c90-63ad-4ac7-a966-58d5c2f81855_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine2_799b7002-92f6-47f6-bde4-77121763b158_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine2_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine2" xlink:to="lab_dei_EntityAddressAddressLine2" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_65f1cde3-1b4b-4115-981f-17210953d9ca_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_361b0863-d1e2-488b-98ac-b542d1942b6b_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_f9cc584c-9823-460a-9ad5-983ce1a04fa5_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_c7932c88-9109-45a3-af56-e2dc9531667f_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>6
<FILENAME>skye-20220518_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:dc1fbabb-1639-4b5a-baab-8e85f16f98d4,g:97730539-3d09-442b-b5a0-dc05c4ac6ccc-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://skyebioscience.com/role/CoverPage" xlink:type="simple" xlink:href="skye-20220518.xsd#CoverPage"/>
  <link:presentationLink xlink:role="http://skyebioscience.com/role/CoverPage" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_1d05e731-7097-48ed-9765-68d1570635b7" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_9695ec7f-fcca-400f-b176-ecc49e029a3c" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1d05e731-7097-48ed-9765-68d1570635b7" xlink:to="loc_dei_DocumentType_9695ec7f-fcca-400f-b176-ecc49e029a3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_da60d983-fafe-4577-9801-277c28db453a" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1d05e731-7097-48ed-9765-68d1570635b7" xlink:to="loc_dei_DocumentPeriodEndDate_da60d983-fafe-4577-9801-277c28db453a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_774f8880-cc25-45ad-a6d3-dd1ff9657f0a" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1d05e731-7097-48ed-9765-68d1570635b7" xlink:to="loc_dei_EntityRegistrantName_774f8880-cc25-45ad-a6d3-dd1ff9657f0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_6160a363-54ec-4f80-91eb-708e99002019" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1d05e731-7097-48ed-9765-68d1570635b7" xlink:to="loc_dei_EntityIncorporationStateCountryCode_6160a363-54ec-4f80-91eb-708e99002019" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_8b5dbb08-b4b8-486e-86bc-6ae8d1761929" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1d05e731-7097-48ed-9765-68d1570635b7" xlink:to="loc_dei_EntityFileNumber_8b5dbb08-b4b8-486e-86bc-6ae8d1761929" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_6eb7cb8c-637b-4e0f-8633-64048dbb1974" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1d05e731-7097-48ed-9765-68d1570635b7" xlink:to="loc_dei_EntityTaxIdentificationNumber_6eb7cb8c-637b-4e0f-8633-64048dbb1974" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_b4ccc848-04e4-4c8d-a9fc-dd4f805a8b98" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1d05e731-7097-48ed-9765-68d1570635b7" xlink:to="loc_dei_EntityAddressAddressLine1_b4ccc848-04e4-4c8d-a9fc-dd4f805a8b98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2_45c268ad-ed65-4a83-829b-d7050cc19b0d" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine2"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1d05e731-7097-48ed-9765-68d1570635b7" xlink:to="loc_dei_EntityAddressAddressLine2_45c268ad-ed65-4a83-829b-d7050cc19b0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_83c48f0a-f954-400d-8392-11bb44a2a664" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1d05e731-7097-48ed-9765-68d1570635b7" xlink:to="loc_dei_EntityAddressCityOrTown_83c48f0a-f954-400d-8392-11bb44a2a664" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_5a143fce-58c9-463a-bc06-b5bf4cc9ec8d" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1d05e731-7097-48ed-9765-68d1570635b7" xlink:to="loc_dei_EntityAddressStateOrProvince_5a143fce-58c9-463a-bc06-b5bf4cc9ec8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_95371545-26f7-4fac-9c15-367cdb5cdcaa" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1d05e731-7097-48ed-9765-68d1570635b7" xlink:to="loc_dei_EntityAddressPostalZipCode_95371545-26f7-4fac-9c15-367cdb5cdcaa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_1d0d3d79-c4c0-4eb3-9efe-cbffd8018188" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1d05e731-7097-48ed-9765-68d1570635b7" xlink:to="loc_dei_CityAreaCode_1d0d3d79-c4c0-4eb3-9efe-cbffd8018188" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_4f202881-2272-460c-a29d-4a50b1842d6c" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1d05e731-7097-48ed-9765-68d1570635b7" xlink:to="loc_dei_LocalPhoneNumber_4f202881-2272-460c-a29d-4a50b1842d6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications_f869ce8d-e8a7-467f-9dd5-465e5cf29833" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_WrittenCommunications"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1d05e731-7097-48ed-9765-68d1570635b7" xlink:to="loc_dei_WrittenCommunications_f869ce8d-e8a7-467f-9dd5-465e5cf29833" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial_b6571e6e-91b2-402d-92e9-e80f763209e5" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SolicitingMaterial"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1d05e731-7097-48ed-9765-68d1570635b7" xlink:to="loc_dei_SolicitingMaterial_b6571e6e-91b2-402d-92e9-e80f763209e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer_92a7ec40-da23-4c25-bb96-7df94450994a" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementTenderOffer"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1d05e731-7097-48ed-9765-68d1570635b7" xlink:to="loc_dei_PreCommencementTenderOffer_92a7ec40-da23-4c25-bb96-7df94450994a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer_5b931327-599f-4e58-a71e-afa26f50438d" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1d05e731-7097-48ed-9765-68d1570635b7" xlink:to="loc_dei_PreCommencementIssuerTenderOffer_5b931327-599f-4e58-a71e-afa26f50438d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_9ca7ba84-25c4-4104-9aa0-5ecd3158ea80" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1d05e731-7097-48ed-9765-68d1570635b7" xlink:to="loc_dei_EntityEmergingGrowthCompany_9ca7ba84-25c4-4104-9aa0-5ecd3158ea80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_938a3ea6-b45d-4dc1-aa34-6a8c4572b469" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1d05e731-7097-48ed-9765-68d1570635b7" xlink:to="loc_dei_AmendmentFlag_938a3ea6-b45d-4dc1-aa34-6a8c4572b469" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_2293e791-ae56-4628-a481-8d1351f2d5a7" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1d05e731-7097-48ed-9765-68d1570635b7" xlink:to="loc_dei_EntityCentralIndexKey_2293e791-ae56-4628-a481-8d1351f2d5a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>7
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139948917571432">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover Page<br></strong></div></th>
<th class="th"><div>May 18, 2022</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">May 18,  2022<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">SKYE BIOSCIENCE, INC.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">NV<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">000-55136<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">45-0692882<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">11250 El Camino Real<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 100<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">San Diego<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">92130<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">858<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">410-0266<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001516551<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>skye-20220518_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2021"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="skye-20220518.xsd" xlink:type="simple"/>
    <context id="i3e6150910ed944fd9b7905d8ded31c91_D20220518-20220518">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
        </entity>
        <period>
            <startDate>2022-05-18</startDate>
            <endDate>2022-05-18</endDate>
        </period>
    </context>
    <dei:AmendmentFlag
      contextRef="i3e6150910ed944fd9b7905d8ded31c91_D20220518-20220518"
      id="id3VybDovL2RvY3MudjEvZG9jOjExODljN2ZiNWQxNDQ0ZDFhYmMxOTRhZjNiNzVhM2U1L3NlYzoxMTg5YzdmYjVkMTQ0NGQxYWJjMTk0YWYzYjc1YTNlNV80L2ZyYWc6OGU3MTdiOWZkMjZjNDlhMmE5Zjc2NjY5NTM5OWIxZTYvdGFibGU6MWEwMTc4ZTEyYzFjNDQzYjgwYzM3ZGU0MjY4NGE1ZWEvdGFibGVyYW5nZToxYTAxNzhlMTJjMWM0NDNiODBjMzdkZTQyNjg0YTVlYV8wLTEtMS0xLTU3ODk0_ef1a55f0-cab6-4469-ba02-958dcd7cb5bc">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey
      contextRef="i3e6150910ed944fd9b7905d8ded31c91_D20220518-20220518"
      id="id3VybDovL2RvY3MudjEvZG9jOjExODljN2ZiNWQxNDQ0ZDFhYmMxOTRhZjNiNzVhM2U1L3NlYzoxMTg5YzdmYjVkMTQ0NGQxYWJjMTk0YWYzYjc1YTNlNV80L2ZyYWc6OGU3MTdiOWZkMjZjNDlhMmE5Zjc2NjY5NTM5OWIxZTYvdGFibGU6MWEwMTc4ZTEyYzFjNDQzYjgwYzM3ZGU0MjY4NGE1ZWEvdGFibGVyYW5nZToxYTAxNzhlMTJjMWM0NDNiODBjMzdkZTQyNjg0YTVlYV8xLTEtMS0xLTU3ODk0_c28e627e-6237-4c88-ade4-dc48ac4f42e2">0001516551</dei:EntityCentralIndexKey>
    <dei:DocumentType
      contextRef="i3e6150910ed944fd9b7905d8ded31c91_D20220518-20220518"
      id="id3VybDovL2RvY3MudjEvZG9jOjExODljN2ZiNWQxNDQ0ZDFhYmMxOTRhZjNiNzVhM2U1L3NlYzoxMTg5YzdmYjVkMTQ0NGQxYWJjMTk0YWYzYjc1YTNlNV8xL2ZyYWc6MzRhMTFjMzU4NmFiNGIxM2I0YTIyYzgzNmQ5NWYwYTYvdGV4dHJlZ2lvbjozNGExMWMzNTg2YWI0YjEzYjRhMjJjODM2ZDk1ZjBhNl8xMTE1_45332661-531f-4978-bcfb-803f76e8dd63">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate
      contextRef="i3e6150910ed944fd9b7905d8ded31c91_D20220518-20220518"
      id="id3VybDovL2RvY3MudjEvZG9jOjExODljN2ZiNWQxNDQ0ZDFhYmMxOTRhZjNiNzVhM2U1L3NlYzoxMTg5YzdmYjVkMTQ0NGQxYWJjMTk0YWYzYjc1YTNlNV8xL2ZyYWc6MzRhMTFjMzU4NmFiNGIxM2I0YTIyYzgzNmQ5NWYwYTYvdGV4dHJlZ2lvbjozNGExMWMzNTg2YWI0YjEzYjRhMjJjODM2ZDk1ZjBhNl8yMzA_37b95c44-489e-4b30-a6d9-2cd4f2a930fc">2022-05-18</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName
      contextRef="i3e6150910ed944fd9b7905d8ded31c91_D20220518-20220518"
      id="id3VybDovL2RvY3MudjEvZG9jOjExODljN2ZiNWQxNDQ0ZDFhYmMxOTRhZjNiNzVhM2U1L3NlYzoxMTg5YzdmYjVkMTQ0NGQxYWJjMTk0YWYzYjc1YTNlNV8xL2ZyYWc6MzRhMTFjMzU4NmFiNGIxM2I0YTIyYzgzNmQ5NWYwYTYvdGV4dHJlZ2lvbjozNGExMWMzNTg2YWI0YjEzYjRhMjJjODM2ZDk1ZjBhNl8xMTE2_40a8f163-be9f-4f5f-bc9d-2d6a098ad92d">SKYE BIOSCIENCE, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="i3e6150910ed944fd9b7905d8ded31c91_D20220518-20220518"
      id="id3VybDovL2RvY3MudjEvZG9jOjExODljN2ZiNWQxNDQ0ZDFhYmMxOTRhZjNiNzVhM2U1L3NlYzoxMTg5YzdmYjVkMTQ0NGQxYWJjMTk0YWYzYjc1YTNlNV8xL2ZyYWc6MzRhMTFjMzU4NmFiNGIxM2I0YTIyYzgzNmQ5NWYwYTYvdGFibGU6NzgzNzI2ZGFjY2JkNDZlMjgxZWQwNzkwOGZjYzkxMmIvdGFibGVyYW5nZTo3ODM3MjZkYWNjYmQ0NmUyODFlZDA3OTA4ZmNjOTEyYl8wLTAtMS0xLTU3ODk0_31179a7d-d3cc-4244-a963-5856a3b46155">NV</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber
      contextRef="i3e6150910ed944fd9b7905d8ded31c91_D20220518-20220518"
      id="id3VybDovL2RvY3MudjEvZG9jOjExODljN2ZiNWQxNDQ0ZDFhYmMxOTRhZjNiNzVhM2U1L3NlYzoxMTg5YzdmYjVkMTQ0NGQxYWJjMTk0YWYzYjc1YTNlNV8xL2ZyYWc6MzRhMTFjMzU4NmFiNGIxM2I0YTIyYzgzNmQ5NWYwYTYvdGFibGU6NzgzNzI2ZGFjY2JkNDZlMjgxZWQwNzkwOGZjYzkxMmIvdGFibGVyYW5nZTo3ODM3MjZkYWNjYmQ0NmUyODFlZDA3OTA4ZmNjOTEyYl8wLTItMS0xLTU3ODk0_f772e67c-982b-4e29-89bd-e76dc86d6746">000-55136</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber
      contextRef="i3e6150910ed944fd9b7905d8ded31c91_D20220518-20220518"
      id="id3VybDovL2RvY3MudjEvZG9jOjExODljN2ZiNWQxNDQ0ZDFhYmMxOTRhZjNiNzVhM2U1L3NlYzoxMTg5YzdmYjVkMTQ0NGQxYWJjMTk0YWYzYjc1YTNlNV8xL2ZyYWc6MzRhMTFjMzU4NmFiNGIxM2I0YTIyYzgzNmQ5NWYwYTYvdGFibGU6NzgzNzI2ZGFjY2JkNDZlMjgxZWQwNzkwOGZjYzkxMmIvdGFibGVyYW5nZTo3ODM3MjZkYWNjYmQ0NmUyODFlZDA3OTA4ZmNjOTEyYl8wLTQtMS0xLTU3ODk0_7e35f3d8-0401-4e30-84a6-7e3ff5de334c">45-0692882</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="i3e6150910ed944fd9b7905d8ded31c91_D20220518-20220518"
      id="id3VybDovL2RvY3MudjEvZG9jOjExODljN2ZiNWQxNDQ0ZDFhYmMxOTRhZjNiNzVhM2U1L3NlYzoxMTg5YzdmYjVkMTQ0NGQxYWJjMTk0YWYzYjc1YTNlNV8xL2ZyYWc6MzRhMTFjMzU4NmFiNGIxM2I0YTIyYzgzNmQ5NWYwYTYvdGFibGU6OWIxZTJjZTYzN2FkNDdhM2FhOTM1MGJmZTdkMDc3MjEvdGFibGVyYW5nZTo5YjFlMmNlNjM3YWQ0N2EzYWE5MzUwYmZlN2QwNzcyMV8wLTAtMS0xLTU3ODk0L3RleHRyZWdpb246NjJiODY3Y2RkNTIxNDc5OGI0YjhmMGNjY2VkYTFjOGJfNA_b3dfcc94-c972-4a99-b9ca-0c585b870642">11250 El Camino Real</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="i3e6150910ed944fd9b7905d8ded31c91_D20220518-20220518"
      id="id3VybDovL2RvY3MudjEvZG9jOjExODljN2ZiNWQxNDQ0ZDFhYmMxOTRhZjNiNzVhM2U1L3NlYzoxMTg5YzdmYjVkMTQ0NGQxYWJjMTk0YWYzYjc1YTNlNV8xL2ZyYWc6MzRhMTFjMzU4NmFiNGIxM2I0YTIyYzgzNmQ5NWYwYTYvdGFibGU6OWIxZTJjZTYzN2FkNDdhM2FhOTM1MGJmZTdkMDc3MjEvdGFibGVyYW5nZTo5YjFlMmNlNjM3YWQ0N2EzYWE5MzUwYmZlN2QwNzcyMV8wLTAtMS0xLTU3ODk0L3RleHRyZWdpb246NjJiODY3Y2RkNTIxNDc5OGI0YjhmMGNjY2VkYTFjOGJfOQ_6c58834e-12ea-4ee5-86e5-8867b7c68ef5">Suite 100</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="i3e6150910ed944fd9b7905d8ded31c91_D20220518-20220518"
      id="id3VybDovL2RvY3MudjEvZG9jOjExODljN2ZiNWQxNDQ0ZDFhYmMxOTRhZjNiNzVhM2U1L3NlYzoxMTg5YzdmYjVkMTQ0NGQxYWJjMTk0YWYzYjc1YTNlNV8xL2ZyYWc6MzRhMTFjMzU4NmFiNGIxM2I0YTIyYzgzNmQ5NWYwYTYvdGFibGU6OWIxZTJjZTYzN2FkNDdhM2FhOTM1MGJmZTdkMDc3MjEvdGFibGVyYW5nZTo5YjFlMmNlNjM3YWQ0N2EzYWE5MzUwYmZlN2QwNzcyMV8wLTAtMS0xLTU3ODk0L3RleHRyZWdpb246NjJiODY3Y2RkNTIxNDc5OGI0YjhmMGNjY2VkYTFjOGJfMTM_132da7b1-5105-4dde-9a8a-00dd12bbbaf0">San Diego</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="i3e6150910ed944fd9b7905d8ded31c91_D20220518-20220518"
      id="id3VybDovL2RvY3MudjEvZG9jOjExODljN2ZiNWQxNDQ0ZDFhYmMxOTRhZjNiNzVhM2U1L3NlYzoxMTg5YzdmYjVkMTQ0NGQxYWJjMTk0YWYzYjc1YTNlNV8xL2ZyYWc6MzRhMTFjMzU4NmFiNGIxM2I0YTIyYzgzNmQ5NWYwYTYvdGFibGU6OWIxZTJjZTYzN2FkNDdhM2FhOTM1MGJmZTdkMDc3MjEvdGFibGVyYW5nZTo5YjFlMmNlNjM3YWQ0N2EzYWE5MzUwYmZlN2QwNzcyMV8wLTAtMS0xLTU3ODk0L3RleHRyZWdpb246NjJiODY3Y2RkNTIxNDc5OGI0YjhmMGNjY2VkYTFjOGJfMTc_4d18a667-5fa0-4a05-9b6b-0cb8ded17566">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="i3e6150910ed944fd9b7905d8ded31c91_D20220518-20220518"
      id="id3VybDovL2RvY3MudjEvZG9jOjExODljN2ZiNWQxNDQ0ZDFhYmMxOTRhZjNiNzVhM2U1L3NlYzoxMTg5YzdmYjVkMTQ0NGQxYWJjMTk0YWYzYjc1YTNlNV8xL2ZyYWc6MzRhMTFjMzU4NmFiNGIxM2I0YTIyYzgzNmQ5NWYwYTYvdGFibGU6OWIxZTJjZTYzN2FkNDdhM2FhOTM1MGJmZTdkMDc3MjEvdGFibGVyYW5nZTo5YjFlMmNlNjM3YWQ0N2EzYWE5MzUwYmZlN2QwNzcyMV8wLTAtMS0xLTU3ODk0L3RleHRyZWdpb246NjJiODY3Y2RkNTIxNDc5OGI0YjhmMGNjY2VkYTFjOGJfMjA_6abebc96-efef-4492-a056-b68eb3bc92bc">92130</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="i3e6150910ed944fd9b7905d8ded31c91_D20220518-20220518"
      id="id3VybDovL2RvY3MudjEvZG9jOjExODljN2ZiNWQxNDQ0ZDFhYmMxOTRhZjNiNzVhM2U1L3NlYzoxMTg5YzdmYjVkMTQ0NGQxYWJjMTk0YWYzYjc1YTNlNV8xL2ZyYWc6MzRhMTFjMzU4NmFiNGIxM2I0YTIyYzgzNmQ5NWYwYTYvdGFibGU6ZTNmZDA3N2EyZTU2NGJjYWExN2JjMmNlZWFkZTU2ZTYvdGFibGVyYW5nZTplM2ZkMDc3YTJlNTY0YmNhYTE3YmMyY2VlYWRlNTZlNl8wLTAtMS0xLTU3ODk0L3RleHRyZWdpb246MWFjNWUxYTY2M2RmNDliYjgwYzZhNDE5NDk1ZDkxNjhfNQ_8b5d58e0-33fd-4c0c-8e6b-eccdb510e50d">858</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="i3e6150910ed944fd9b7905d8ded31c91_D20220518-20220518"
      id="id3VybDovL2RvY3MudjEvZG9jOjExODljN2ZiNWQxNDQ0ZDFhYmMxOTRhZjNiNzVhM2U1L3NlYzoxMTg5YzdmYjVkMTQ0NGQxYWJjMTk0YWYzYjc1YTNlNV8xL2ZyYWc6MzRhMTFjMzU4NmFiNGIxM2I0YTIyYzgzNmQ5NWYwYTYvdGFibGU6ZTNmZDA3N2EyZTU2NGJjYWExN2JjMmNlZWFkZTU2ZTYvdGFibGVyYW5nZTplM2ZkMDc3YTJlNTY0YmNhYTE3YmMyY2VlYWRlNTZlNl8wLTAtMS0xLTU3ODk0L3RleHRyZWdpb246MWFjNWUxYTY2M2RmNDliYjgwYzZhNDE5NDk1ZDkxNjhfOQ_677d86e4-d259-490f-a39d-45abe8ec396f">410-0266</dei:LocalPhoneNumber>
    <dei:WrittenCommunications
      contextRef="i3e6150910ed944fd9b7905d8ded31c91_D20220518-20220518"
      id="id3VybDovL2RvY3MudjEvZG9jOjExODljN2ZiNWQxNDQ0ZDFhYmMxOTRhZjNiNzVhM2U1L3NlYzoxMTg5YzdmYjVkMTQ0NGQxYWJjMTk0YWYzYjc1YTNlNV8xL2ZyYWc6MzRhMTFjMzU4NmFiNGIxM2I0YTIyYzgzNmQ5NWYwYTYvdGFibGU6Njk5MmNlY2JjYjdiNGZmZGE1ZGFhYzA4MmZjMDU0ZDcvdGFibGVyYW5nZTo2OTkyY2VjYmNiN2I0ZmZkYTVkYWFjMDgyZmMwNTRkN18wLTAtMS0xLTU3ODk0_401ce26e-387d-4d3a-ab36-3586e687531f">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial
      contextRef="i3e6150910ed944fd9b7905d8ded31c91_D20220518-20220518"
      id="id3VybDovL2RvY3MudjEvZG9jOjExODljN2ZiNWQxNDQ0ZDFhYmMxOTRhZjNiNzVhM2U1L3NlYzoxMTg5YzdmYjVkMTQ0NGQxYWJjMTk0YWYzYjc1YTNlNV8xL2ZyYWc6MzRhMTFjMzU4NmFiNGIxM2I0YTIyYzgzNmQ5NWYwYTYvdGFibGU6Njk5MmNlY2JjYjdiNGZmZGE1ZGFhYzA4MmZjMDU0ZDcvdGFibGVyYW5nZTo2OTkyY2VjYmNiN2I0ZmZkYTVkYWFjMDgyZmMwNTRkN18xLTAtMS0xLTU3ODk0_850a437d-fbbc-489d-a406-da266f4956a9">true</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer
      contextRef="i3e6150910ed944fd9b7905d8ded31c91_D20220518-20220518"
      id="id3VybDovL2RvY3MudjEvZG9jOjExODljN2ZiNWQxNDQ0ZDFhYmMxOTRhZjNiNzVhM2U1L3NlYzoxMTg5YzdmYjVkMTQ0NGQxYWJjMTk0YWYzYjc1YTNlNV8xL2ZyYWc6MzRhMTFjMzU4NmFiNGIxM2I0YTIyYzgzNmQ5NWYwYTYvdGFibGU6Njk5MmNlY2JjYjdiNGZmZGE1ZGFhYzA4MmZjMDU0ZDcvdGFibGVyYW5nZTo2OTkyY2VjYmNiN2I0ZmZkYTVkYWFjMDgyZmMwNTRkN18yLTAtMS0xLTU3ODk0_d561d588-d0f6-4593-816c-a0400a7c9676">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer
      contextRef="i3e6150910ed944fd9b7905d8ded31c91_D20220518-20220518"
      id="id3VybDovL2RvY3MudjEvZG9jOjExODljN2ZiNWQxNDQ0ZDFhYmMxOTRhZjNiNzVhM2U1L3NlYzoxMTg5YzdmYjVkMTQ0NGQxYWJjMTk0YWYzYjc1YTNlNV8xL2ZyYWc6MzRhMTFjMzU4NmFiNGIxM2I0YTIyYzgzNmQ5NWYwYTYvdGFibGU6Njk5MmNlY2JjYjdiNGZmZGE1ZGFhYzA4MmZjMDU0ZDcvdGFibGVyYW5nZTo2OTkyY2VjYmNiN2I0ZmZkYTVkYWFjMDgyZmMwNTRkN18zLTAtMS0xLTU3ODk0_1b893c46-3e0a-4d03-bc4c-9e511454f849">false</dei:PreCommencementIssuerTenderOffer>
    <dei:EntityEmergingGrowthCompany
      contextRef="i3e6150910ed944fd9b7905d8ded31c91_D20220518-20220518"
      id="id3VybDovL2RvY3MudjEvZG9jOjExODljN2ZiNWQxNDQ0ZDFhYmMxOTRhZjNiNzVhM2U1L3NlYzoxMTg5YzdmYjVkMTQ0NGQxYWJjMTk0YWYzYjc1YTNlNV8xL2ZyYWc6MzRhMTFjMzU4NmFiNGIxM2I0YTIyYzgzNmQ5NWYwYTYvdGV4dHJlZ2lvbjozNGExMWMzNTg2YWI0YjEzYjRhMjJjODM2ZDk1ZjBhNl8xMTE0_e7f0d6b2-4ac2-46e7-917b-fce0b8ee78c7">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>9
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M._5,\\L8LL/A\]KM>KA,8$OUM%P>*1^N=S)1M>M3W*3_1S8QI@"RDX"X["G
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M:%0*CMQC)8QQ8K3^-8+)#^Q^ %!+ P04    " "AB+=4&445]3<!   G @
M#P   'AL+W=O<FMB;V]K+GAM;(U1T6[", S\E2H?L!:T(0U17D#;D*8-C8GW
MT+K4(HDKQX6-KY_;JAK27O:4W-FZW%T6%^+3@>B4?'D78FYJD6:>IK&HP=MX
M1PT$G53$WHI"/J:Q8;!EK '$NW2:9;/46PQFN1BUMIS> A(H!"DHV1%[A$O\
MG7<P.6/$ SJ4[]ST=P<F\1C0XQ7*W&0FB35=7HCQ2D&LVQ5,SN5F,@SVP(+%
M'WK7F?RTA]@S8@\?5HWD9I:I8(4<I=_H]:UZ/(,N#Z@5>D(GP&LK\,S4-AB.
MG8RF2&]B]#V,YU#BG/]3(U45%K"FHO409.B1P74&0ZRQB28)UD-N5G0&3K;V
M"%TH?653#@%%G=W4Q7/4 6_*P>-HK(0* Y1OJA65UY**+2?=T>M,[Q\FCUI&
MZ]Q*N??P2K8<<XY_M/P!4$L#!!0    ( *&(MU0D'INBK0   /@!   :
M>&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'.UD3T.@S ,A:\2Y0 U4*E#!4Q=
M6"LN$ 7S(Q(2Q:X*MR^% 9 Z=&&RGBU_[\E.GV@4=VZ@MO,D1FL&RF3+[.\
MI%NTBB[.XS!/:A>LXEF&!KS2O6H0DBBZ0=@S9)[NF:*<//Y#='7=:7PX_;(X
M\ \PO%WHJ45D*4H5&N1,PFBV-L%2XLM,EJ*H,AF**I9P6B#BR2!M:59]L$].
MM.=Y%S?W1:[-XPFNWPQP>'3^ 5!+ P04    " "AB+=499!YDAD!  #/ P
M$P   %M#;VYT96YT7U1Y<&5S72YX;6RMDTU.PS 0A:\295LE+BQ8H*8;8 M=
M< %C3QJK_I-G6M+;,T[:2J 2%85-K'C>O,^>EZS>CQ&PZ)WUV)0=47P4 E4'
M3F(=(GBNM"$Y2?R:MB)*M9-;$/?+Y8-0P1-XJBA[E.O5,[1R;ZEXZ7D;3?!-
MF<!B63R-PLQJ2AFC-4H2U\7!ZQ^4ZD2HN7/08&<B+EA0BJN$7/D=<.I[.T!*
M1D.QD8E>I6.5Z*U .EK >MKBRAE#VQH%.JB]XY8:8P*IL0,@9^O1=#%-)IXP
MC,^[V?S!9@K(RDT*$3FQ!'_'G2/)W55D(TADIJ]X(;+U[/M!3EN#OI'-X_T,
M:3?D@6)8YL_X>\87_QO.\1'"[K\_L;S63AI_YHOA/UY_ 5!+ 0(4 Q0    (
M *&(MU0'04UB@0   +$    0              "  0    !D;V-0<F]P<R]A
M<' N>&UL4$L! A0#%     @ H8BW5,P%^,_N    *P(  !$
M ( !KP   &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#%     @ H8BW5)E<G",0
M!@  G"<  !,              ( !S $  'AL+W1H96UE+W1H96UE,2YX;6Q0
M2P$"% ,4    " "AB+=4 1UAV]T#   !#P  &               @($-"
M>&PO=V]R:W-H965T<R]S:&5E=#$N>&UL4$L! A0#%     @ H8BW5)^@&_"Q
M @  X@P   T              ( !( P  'AL+W-T>6QE<RYX;6Q02P$"% ,4
M    " "AB+=4EXJ[',     3 @  "P              @ '\#@  7W)E;',O
M+G)E;'-02P$"% ,4    " "AB+=4&445]3<!   G @  #P
M@ 'E#P  >&PO=V]R:V)O;VLN>&UL4$L! A0#%     @ H8BW5"0>FZ*M
M^ $  !H              ( !21$  'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR
M96QS4$L! A0#%     @ H8BW5&60>9(9 0  SP,  !,              ( !
M+A(  %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&      D "0 ^ @  >!,

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>20</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="skye-20220518.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001001 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://skyebioscience.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="skye-20220518.htm">skye-20220518.htm</File>
    <File>projectfran-ehtsupportagre.htm</File>
    <File>projectfran-skyesupportagr.htm</File>
    <File>skye-20220518.xsd</File>
    <File>skye-20220518_lab.xml</File>
    <File>skye-20220518_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="20">http://xbrl.sec.gov/dei/2021</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>14
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "skye-20220518.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "contextCount": 1,
   "dts": {
    "inline": {
     "local": [
      "skye-20220518.htm"
     ]
    },
    "labelLink": {
     "local": [
      "skye-20220518_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "skye-20220518_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "skye-20220518.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.sec.gov/dei/2021/dei-2021.xsd"
     ]
    }
   },
   "elementCount": 21,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2021": 2,
    "total": 2
   },
   "keyCustom": 0,
   "keyStandard": 20,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "skye",
   "nsuri": "http://skyebioscience.com/20220518",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "skye-20220518.htm",
      "contextRef": "i3e6150910ed944fd9b7905d8ded31c91_D20220518-20220518",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001001 - Document - Cover Page",
     "role": "http://skyebioscience.com/role/CoverPage",
     "shortName": "Cover Page",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "skye-20220518.htm",
      "contextRef": "i3e6150910ed944fd9b7905d8ded31c91_D20220518-20220518",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://skyebioscience.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://skyebioscience.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://skyebioscience.com/role/CoverPage"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://skyebioscience.com/role/CoverPage"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://skyebioscience.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two",
        "terseLabel": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://skyebioscience.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://skyebioscience.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://skyebioscience.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://skyebioscience.com/role/CoverPage"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://skyebioscience.com/role/CoverPage"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://skyebioscience.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://skyebioscience.com/role/CoverPage"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://skyebioscience.com/role/CoverPage"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://skyebioscience.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://skyebioscience.com/role/CoverPage"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://skyebioscience.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer",
        "terseLabel": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://skyebioscience.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer",
        "terseLabel": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://skyebioscience.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material",
        "terseLabel": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://skyebioscience.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications",
        "terseLabel": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://skyebioscience.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 0
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12"
  },
  "r3": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r4": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>15
<FILENAME>0001516551-22-000013-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001516551-22-000013-xbrl.zip
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M^Y,8A O" N9<@(Q)S7\D_[ @LR+PCCF?!)\'O-(BU\[:^)C=,#RI@6'(1S(
M2JOE3^JS@SO'),_(1<"@<Q D:4@X#Y+'R%@4P?9!5@Z^B&BVP.$1\%D*NP(B
M-C*!*A]@H.*O:3')@RFB5D#I75,FQ<F?&B @E?) B@MJ8+H!+*/)DS1#+[SW
MZ@W+_\S>)^(A[%W!(8H#,XF8A]GWNG\B[\=BT6%[6'2OTR5HA>A,X)"Q I+5
MLQ;,@FP%"N^,R>'&9!A!A T4-@*R<!+J/I%B4N1>!&23"\N@L.>4AKUO.0(C
MW(4HD; =:8\4MTD^. ] 8W.ND/URN(,_RYYB3OBN.0$TQ^B/WQ%A$>,SP8=]
MQG( M\8ZT%FF@(OGTZ=+9DS+V -,"P89$ULN@):P#JSX/2MQ_K-X%7Q0-G\?
MGM/UO^_T6$V#,#:WC$5RR7&\ZO&8F0$Y)[9A"!(Y!'H0.Q.=,(+8D="#P= )
M1U0%CYFD(Q7+]L.NAE(?FC%ZHR0L?Y%4W3!P1^<&:-T#R\%08()'RH93RD_+
MN_MBJ8AX]S;L;"T+Q&!.L_D9J4G&VP@L3K\; #=M,GY6X9TWK#F<(H.)/0X+
ME(:4KYY6S@R*>!-;:L?%CR)YI^#!PW%)_0%\)6GS3<MHU5Z(JH '"(VDLM*&
M@%GYW#&9]8,$=>081,9(8=")!6V1PDM8: V\YY<Q+7PU!AX5:JX@JC[/QJ(=
M_<JS\"MO Y01.")EV*NF'4O7 !:*3?\&X@/B4KQX-"KL,VPT[ZGFA4B) &Y2
M0^C-+T4<\#J&&K0;/,B7(ASQK&"JN,>^EQ81;V"J1X50AR.]Q!>:T]PL=X&\
MB'8"!7O,&Q)$JD"X&E$ALC5-D\*&*5M :@#RC+&<(@9Q;^>$'C&,7]&L+X1*
MD[545L%*[+:"GC9@3)O4I7%4WB'(E@RA2:SR92HP@7S:S$GX[")=&K[]>UVB
MX-/Q N#Z$5O K08J,]GR=;D_5"I[YX=(9:,)"R;U*K,ZE&V^)5W=1'FW)*^;
M!<.WI;*_$671>DNU?;EL@1RP#40H^P%AM&1#J[I^E!Q6'CF(<*ZHY"@!N5KD
M"MZGJI*]DS7=\!;F^YSP 3D'F<EU612KG?BNJ#Z)*U#-A< BF\()5B/-FK2E
M EKG(%$K0_JXR\,".'K!EH[55^V[&XM7!"")IU@AXU2ES'L0U@=K<F+7>9];
M&/O-ORTH1W+_@6&X9M?W>P3E.,"W1!CN.;7^G%K?\G;6*;7^'%ENC[QO7_*'
M\!%E_I72/Y,T";0.*? +8A+>@OC-.,JD6;H.-$A2O2@R2Y$+<?A*KZX2P_D5
M-9+#E)\:*8P627WM7*T@^8$<^I@+:TA($18E%I_ "7+8BMG%5J:$BQNCYLM:
MH#*(O%MAF "AXVM:2+#;ONB+4UF2>/^'@(TJ<]V^^@%;3863%H["_Y%U&.-A
MW>@YF,=,J:H  8((##Q;6+[I>U?@#&!2&&$C6*B%E_'X*OR2%"P:2'8D63Y)
M8EN30[^GR[F@+)8.!V7F :.[("5L7NA!TY3;5-"#P*1!,<8X-J*)*9@D2!2+
M@K%W+3$T54J*VP" &DRJ$,8=TS((>BHP$;#AEH]BM*,%V/ /3 EM@(3[37$_
M23!AU@:#[G,80;M'52(LU6C; X-2,JDYE(B?SA5-##C]0U_.#5<'(U9<_UPO
M\Z0V"X'DD")FBRUL#6E.6Y=)[U"I.\4-##$BA:EBBAP+V:-D&*IKD%4-\<@Z
M=(5B'BC:!-=29L-QB")%(B1_TO;=L)1)R??:2.+N-M<$-LEQY@$598DP </J
M^+E!$0WP!@4A#AF'2.(+G]7MK*!!Y($IDUT10MW[=Y&DQ1@%MKL@ZVZ%MS"(
M^KU)VAK6>"&71].G0K8;#OYNMG&,0_N2.]F@!.?4.W+*%#ZE"="4BDI2H>@!
M)VLW'3W+@%O7D ?;/TMB($*!DXQ4&C+-#C3.,01^"G)"R][ 5R3=(_,5+7^T
MR5,P-C"O&^I(H7LZGNA0LWJ'&PW1F2GKL$I$F@/-<A[O 8'%!5;SB@B:PF[H
MOJG<[FJO"X0Q13E@V!?#+1'B\#F7/8?X .JS"+]2T[)@J2)]3@>.P50R_>S\
MEP7ZX-,#.6UDFQ:9-$B2KUL#A<79V30#$>@E$T0WL!0\/KGPCB.M4JZ9"4$D
M4K ,03T7.KTV:*!1OSL'8( Q#?!0\1KP)M&P6HPF8+Z9XRM<$P8V5-QC@Y&;
MEAG$?)-X1E:5YJA1"=9P\54E\9:@0C43.&7@]T;=K(1=0BX6%'>%G]C$KQ-X
M7%J;C']L+4S&3V.X\]J$!4*O0YT!,;KJQ6DXA6]-3! BUFMH 6,0)S19I@F8
MTOB[6=,<ORX)R2Z<W9=J+C!;<L(1-L:KPBE!?LT$(SG!VK8,:!E0(.3NK6[7
MT;9$D.*Q\%N!^?LVKP R!Z.3;-BIK]K1X01$@><*4ZSQ(AP.2Q,**5O "3WD
M/;<N9#I>B%FM"]Y:<*)"G<S&J*LD"EL8Z]H_8*]];O\9.?NXRY=89M%"5Y]$
M.-"XDWQ'BF>\Y0(4/WI(4I2"7>2 Q*7&A))\#";+\R2-];2LEA3R=],Z%E'7
M5&/"B*UFZX8@3L0G#65>90<M52MP8:G#T6SYT6R)B=RUUESQKC(8V]]+1JO@
MK+Y;KN TPZE5X="(#,)93X[<;Q]'5BUH<->:S--5LBBX<;\MT=M.PC_-QC5W
MM<7.,G4JO+W XA;?TF_ZZ1B46&9M.&RD=JZ!!H6Q/V$V(,M*U]?Y+6K))+HF
MKHG!R,&?.JX  :!3A)R6=8 W(*FBZ5;"_%T,,H-&'/&8&_+#'Z<4:AMB#G@B
MZX&Y8W1L,]GQLNJ3%#9ZXN0CX#0DEU#KF$GEU"3EN# <@;M@.TYP*/ZH[AG9
MI(0C.-TI;X*9 :X'6Q:4ZT9#0!Q_S@SCDB;/ +0G#0[A;K&1R60AKV=J[(&:
M-)ERX'D@\KDJQB_!T*6M7QE\CCJY4M>68S*P&CUPQN-D; )!N!'DC>ZR6742
M($V&C!;56)!HS,,E8 EAK5B72Q$$+]ZXVD2(A<X;NB(V%W%4C60;.+).T;=S
MKWLMF>^^8_)'4PFR4RIN-$+/W@;2!6>_W?V;.Z1UT1,VM$/GL9YA&,\PC"UO
M=YU@&*(<YQDID? 8%5^8P3*,0D&P@O@SUN@G!I*)6G03#M-A>&ZP.3MZE2U#
M">&TLJX:WDK+%:?":\,V6) <6YYL,HZ[B@\Y5\/DKW6:&P9>86/T%",B:6 R
M;IN2E@*8WF- YI:[;\JCKC,RL(4QZ@6:%0,J6]0 >6!"G_NBRVNPY3B!-I1:
M&MIB^S['4'"13IVNYU;3NMI1%,W0*3"&H6TPN:K^NL6J(^6?,G"EGN_+K@Q=
M>1M/W,8'5@4_&>FO,\VW#_5,WH*TEZJ5P8UU.D(:5F,5C=38*6%E(5T97HYI
M.;!G)("X'I25@. O.(60^%Z:A9>??,$0L'=MR_4PRBZDB^8JD(B](89RT:P1
MH[(.UFMVW,19(A]GE1;?HZC'NQ7BFG)2"W'E5>"P@2"S&8JTWE0)&AU*B2=]
M@%+Q&ERK*FF):,01<,GHP36(+=B]5^V+M)TE>)2+I$O.=5B LGZ/25ESA<T;
M$7%9!(& 1$\P-;OB6L3E@' F_\:8N=A!5@+:=R"!$[?(5S-F=G8HMWSS6L9+
M?#< 7J;LGX%%3ZGN484$7%,.UA95%::$8,:8#9XA$B1%JD:5H4I)WZ$*$'AL
M<X5-D=RJ3QT9HACOM$%-AJ^A19RY4<-;AQ*%. ^GT'].+'@"(ULA#[08N;&F
ME-5"YZE"HF,=$K9@@#?<<<&(*U]15(FCX&9P['AE09%EMMU##.H.*93>EY!9
M<8%F@]B; K-AA,4#R<JQ[CA\^E<ELA9Z*P'"!GR!*E,M9IBDF>:N%]C20R-2
MR+;TLHT$A2H)*3@  1A-13AQ.Y.Y09M_CH05:4)[26J&>H>4*5>J))&*GUK?
MD)I?18(0AZ[U&9GIB/@7)+86&O3#(HWQ:#W6:Q6P2'27R*(F<+\EKW"A)*I$
M(7B(!GM:.DJ6",]J8K26QNHK9^ZEL8_ RZSHO%'32@#ZMT,9UY1\VE=W)J:6
MBSBASME:6O\(C%!R9GRQDMB%ETS*KK <4<,<MLZ=/K'<AJ(9O38+ 5W?,$ +
M&]DQ/SL2PK='\Y6!6XPH"4>G%'V+K>'B1(0E ,P;KZ7!'((!4F7BN@B!Z5^3
M*IN!")/K=F4&)E^67-:TP]%!*P,.)XA+C?/VP>R6"20X']P92Y!T@+9V/H'H
M)+E6-WR:<*]-B&>>X(VBZ *UQ*;BD<;B*<2N*3H%VIZ#P* _,/>4$75<?6RG
M5QY-<#F3J6EL3+BHA3""@_$HK37EJ\/V\=5E"6#',S.K$U56S&5]!CR7,I?+
M%AHJ0&T%>5,73XM<::8U9@'@Q]M#:L\ D[\0P&3O40 FK9$_+8RP-L?-P42+
MH@IQYWLC,\RIDQ L:]V8XQ,A*+?GI,Y=C+FP?M-1(;7>5-,%08C&Z(-C&!+>
MA235AG-$$)\$Y!Y8@35JJ;E6W.VN#O>KVN"5N$'WJ M;TQ2H#('H>1Y5C2DJ
ME %A3@4\+Y@%!W@@;6,)GF'1&13D<S 9FS[WC<4"/,[N-DA65-)8 EB:*7R0
M4>97S1UK=0$NXL%6Q7,@B6IE/20+:?G+"']VPJAPL,1<SNT>FN^S@%ZW@@:<
MQ#P)OGJ4G*8P5ZKS(J7,?7GX]FTI\0VJHAN2%Z*ID"Z IP!G ON9E#5 <_/*
MDG+26 M 1E^ F%(IG7/:[M21W]5QR-+@]M9G5V5'O5IN7URG!5S%,.ND/)7A
MUD/3I:MM,AY+T3/\H/23[ "6[&9+F5PB\C:.-GFQRB>Z\P%*Y8PI$*.O)609
M\4(VMKI.Y'RLY3IRWPJ1I3O<U<6_/)UEIC92JM5@^HU2Y[:Z-=_;^'43%V^,
MMH\8.[;W]'!F#4WF+',BAM#&\68%Z$?/5I=N"4UND!1QN>=NW5B-=VSG[;(I
M,@9ZJ:8=)R6UGM9%5N&UBILF2)1\,C<?F^&P4VHU)?O4NP0+E4@1EM6S5!A1
MRNP3)0=B."X@(=1J"X+/CO1K'SQ+G-G[I8=HQE3)FE.!LUW+9EE#)^/);.RE
M2?K<[_1IX]Y<+5>W)F8S< O/&YP_:+!F1=QQT.#F$Q\T*%;%HE/7RH>I'[\F
MIZVM;UBUA9D_A(NXCF^3#2'Q=<<BH9R=T4 K$^K1YIX/ #23XK\44S6EY5I:
M=%7QU1W'KRX.[MP#K?_+VT'ZRW(#M3TJU.NV)RRTW=GFEF:.3=[B7F9NR)7J
MH)SC@1<?-C;3<:L%_;8:E[L-W;<6=]%8&%<3MRY;!*WG8RRXZT-9)TXF&7JE
MOE,_>=O1/4[?D=F&-95?.FQV31>ZI51*PJ['K*>VN%6U?,U%?W_FY)9GTF1L
MZJ!C:M+W2D<+CRXKZ364-O8+>F/SA(1ZK>=,VU;2M'N"7OT;MZ+>EA7SZ?'N
MU[,_Q\D5F1S9ANX &:RT$]RM:*92WG%I!YNEA<L.#IBWZ-H,Q9,0K='("9:F
M:,GX+-$%M%>OO9U;NS7-*_1Z[=,@)R8+HB0#$Z"]:B.1D%FN3-3$VMR "D]6
MP_B H$>HX-S&(OS&%CI4>"%/7SK3+.F*-*\.MD).0.CT7)L=N'3)#+3M3=LX
M<ZI'+S%<ZAH>DP_0JC5MLF<1<=CC@CLRH:_01R69)K$)O!/[$$? F=/,<!;Q
M7(,EJ+$'YL9%_^3H?+.43>Y/5:Z\WQ7*7 JWV!'\F2&D%=1&_^1W&.F1B&:Y
M1,!*D>K]\F2_V</YDOKQ>A3>+ /><C'353+3AHHSSF4KB'HHK$D'W8F)US$1
MMUR![9VR)! AC 98)9/#A'\ZMGV6F"#A99P4<5!ZJ?(QGL\E3]'4E.6.)A=+
M'R)11OWFLXMN8U=JX+*F2F.[?4J#A-Y1=?(3T<&*]0<?9,$,<9^#J3C46O4&
MQU/((^J@=H7"[XIM:.2=\GA=[A$Q%W)Q-0/3M+)T>^<AC!A"IX9]\&%8AF9
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M<1!D@92H_1TDX13^N<K'T2__#U!+ P04    " "BB+=4#"UF,),J   %3 $
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M1<,MB6Z)T^+()HF-OT@%&BE"XFT5]1U(MVB\E;!,*/J90H>"^-*-0../4U+
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MJ%[0:F*)4:Y Y]!G/H7C_ACO[V].#E\F^G%#G4N6ROM8=!<\IUIYP_0_TO"
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M=MK-4SMG*L.N96".-%?7)#I.F L5U<D#[NF)]R1C5$1#LJ@]BXG ^!7X&'4
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M&C:!7'7]W!R='*U?299?.7IR]']02P,$%     @ HHBW5+%RIX9 !@  !BT
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MX.SAWG\!4$L! A0#%     @ HHBW5,4ZB;HW)P  Y!@! !X
M ( !     '!R;VIE8W1F<F%N+65H='-U<'!O<G1A9W)E+FAT;5!+ 0(4 Q0
M   ( **(MU0,+68PDRH   5, 0 >              "  7,G  !P<F]J96-T
M9G)A;BUS:WEE<W5P<&]R=&%G<BYH=&U02P$"% ,4    " "BB+=4OR8:4T<;
M  #YP   $0              @ %"4@  <VMY92TR,#(R,#4Q."YH=&U02P$"
M% ,4    " "BB+=4G_V7UG$"  "!!P  $0              @ &X;0  <VMY
M92TR,#(R,#4Q."YX<V102P$"% ,4    " "BB+=4\.YC<H<)  ! 5@  %0
M            @ %8<   <VMY92TR,#(R,#4Q.%]L86(N>&UL4$L! A0#%
M  @ HHBW5+%RIX9 !@  !BT  !4              ( !$GH  '-K>64M,C R
C,C U,3A?<')E+GAM;%!+!08     !@ & )P!  "%@      !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
